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GENERAL INTRODUCTION: CURRENT STATE OF RESPONSE PREDICTION IN CLEAR CELL RENAL CELL 
CARCINOMA TREATED WITH ANTI-VEGF-TARGETED THERAPY 
 
 
Until 2005, metastatic clear cell renal cell carcinoma (m-ccRCC) was a disease difficult to treat: it was resistant to 
chemotherapy and immunotherapy seemed only to be helpful in a small subgroup of patients difficult to identify in 
advance. Since 2005, targeted therapy directed against the vascular endothelial growth factor (VEGF)-pro-
angiogenic pathway has replaced immunotherapy. Targeting the VEGF-pathway was based on the discovery that 
clear cell renal cell carcinomas (ccRCCs) are highly hyper-vascularized tumours, probably due to the very 
frequent dysregulation of the von Hippel-Lindau (VHL) gene leading to amplification of hypoxia induced factor 
(HIF)-mediated gene transcription and up-regulation of VEGF-dependent angiogenesis (1).  
VEGF-directed monoclonal antibodies such as bevacizumab and anti-VEGF-receptor (VEGFR)-tyrosine kinase 
inhibitors (TKIs) such as sunitinib, pazopanib, and sorafenib, have improved the outcome of m-ccRCC patients, 
significantly prolonging the median progression-free survival (PFS) compared to immunotherapy or placebo (2-4). 
Some 40% of patients will achieve a reduction of the size of their metastases or primary tumours. In an additional 
40-45% of patients, there will be disease stabilization under the therapy. Moreover, long-lasting or complete 
responses are obtained in a limited number of patients. Other compounds such as temsirolimus and everolimus, 
which are antagonists of the mammalian target of rapamycin (mTOR), another key protein in the regulation of 
intracellular signal transmission, have shown activity in the treatment of metastatic RCC (mRCC) (5, 6). 
Nevertheless, despite the convincing results of anti-VEGF-targeted therapy, some 15-20% of the patients are 
primarily resistant to these compounds and most of the patients who initially respond to the therapy will eventually 
develop secondary resistance and relapse after more or less one year of treatment (7). If the tumour is resistant 
from the start of the therapy, this is called “primary resistance”. If the tumour develops resistance after some time 
on anti-VEGF-targeted therapy, this is called “secondary resistance”. 
In several other tumour types molecular markers predictive for response on targeted therapies have been 
discovered: BRAF-mutations for vemurafenib in melanoma, c-KIT-mutations for imatinib in gastro-intestinal 
stromal tumours (GIST), KRAS-mutations for cetuximab and panitumumab in colorectal carcinoma, EGFR-
mutations for gefitinib and erlotinib in non-small cell lung carcinoma, the abl-bcl fusion gene for imatinib and 
dasatinib in chronic myeloid leukaemia, ALK-mutations for crizotinib in non-small cell lung carcinoma, and 
HER2/neu-amplification for trastuzumab or lapatinib in breast cancer. Unfortunately, there are no validated 
markers predicting response in m-ccRCC patients treated with anti-VEGF- or mTOR-targeted therapy. 
Several clinical markers associated with PFS and overall survival (OS) were described and validated. They have 
been combined in scores such as the Memorial Sloan Kettering Cancer Center (MSKCC) (8) and International 
Metastatic Renal Cell Carcinoma Database Consortium (IMDC) score (9), described in paragraph 5 of the general 
introduction, but they have a prognostic rather than a predictive value. The clinical and biochemical parameters 
described until today do not allow us to predict resistance in individual patients nor to preclude patients from anti-
VEGF-targeted therapy. 
Therefore, the aim of this project was to investigate a variety of clinical, biochemical, pathological, and molecular 
or genetic markers of potential prognostic and/or predictive value in the context of anti-VEGFR-TKIs in m-ccRCC 
patients. Reliable response prediction could help us to better define the prognosis for a given patient and to 
improve our understanding of the mechanisms of primary and secondary resistance. This will eventually allow us 
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to improve the outcome of m-ccRCC patients by a more rational use of targeted therapies, possibly avoiding 
unnecessary adverse events in resistant patients and potentially saving costs. Some mechanisms of resistance 
may be relevant to the whole class of anti-VEGF-targeted therapies, others will likely only apply to individual 
compounds. In that case, a better understanding of the mechanisms of resistance will also allow us to define the 
best therapeutic options and help us to optimize the sequence of the available treatments.  
 
1. EPIDEMIOLOGY, CLINICAL COURSE, DIAGNOSTIC AND THERAPEUTIC APPROACH IN RENAL CELL 
CARCINOMA 
 
Renal Cell Carcinoma (RCC) accounts for about 2-3% of all adult malignancies, representing the seventh most 
common cancer in men and the ninth most common cancer in women (10). There were 46.151 new cases in the 
European Union in 2008 (11). In Belgium, in 2010, 1.532 patients were diagnosed with kidney cancer. RCC is 
approximately 50% more common in men compared with women and occurs predominantly in the sixth to eighth 
decade of life with a median age at diagnosis around 64 years. In developed countries, RCC is the tenth most 
common cancer-related cause of death. 
RCCs, which originate within the renal cortex, constitute 80 to 85% of primary renal neoplasms and present 
several distinct subtypes, including ccRCCs (75-85%), papillary or chromophilic RCCs (10-15%), chromophobe 
RCCs, oncocytomas and collecting duct carcinomas (Bellini duct) (12). Fuhrman et al. described the most 
commonly used gradation of ccRCCs (grade 1 to 4) (13).  
Many patients are asymptomatic until the disease is in a more advanced stage. The most common presenting 
symptoms are haematuria, abdominal mass, pain, and weight loss. Haematuria (in up to 40% of patients) is 
observed with tumour invasion of the collecting system. Fever (in 20% of patients) is usually intermittent and 
frequently accompanied by night sweats, anorexia, weight loss, and fatigue. Inferior vena cava involvement can 
produce lower extremity oedema, ascites, hepatic dysfunction and pulmonary emboli. Among patients with 
disseminated disease, signs or symptoms depend on the site and extent of the metastases. The most common 
sites are lung (70%), regional and thoracic lymph nodes (60%), bone (35%), liver (25%), brain (7%), the ipsilateral 
adrenal gland and the contralateral kidney. Paraneoplastic symptoms are not uncommon: anaemia, 
erythrocytosis (present in 1 to 5% of patients due to constitutive production of erythropoietin), thrombocytosis, 
hepatic dysfunction and hypercalcemia.  
Around three out of five RCC-patients present with localized disease (confined to the kidney), one out of five with 
regional disease (spread to regional lymph nodes) and one out of five with metastatic disease. A rise in the 
incidence of localized disease and a reduction in the incidence of regional and metastatic spread as well as a 
steady decrease in the size of tumours at presentation, were seen during the last years, likely due to the greater 
number of incidental tumours detected on abdominal imaging performed for other purposes.  
Although with state-of-the-art imaging techniques the histological diagnosis of solid renal masses can be 
predicted in many cases, a definite histological diagnosis can only be achieved by analysis of a biopsy or a 
specimen. For patients with isolated, solid renal masses, resection with either a partial or complete nephrectomy 
is preferred to biopsy, because it provides both the diagnosis and serves as definitive treatment. When metastatic 
disease is suspected at initial presentation, pathologic confirmation of at least one disease site is required prior to 
starting therapy. Biopsy of a metastatic site is often easier and more informative than biopsy of the primary 
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tumour. The Tumour Node Metastasis (TNM) staging system, revised in 2010 (14), defines the anatomic extent of 
disease and stage (Table 1 and 2).  
PRIMARY TUMOUR (T) 
TX Primary tumour cannot be assessed 
T0 No evidence of primary tumour 
T1 Tumour 7 cm or less in greatest dimension, limited to the kidney  
T1a: Tumour 4 cm or less in greatest dimension, limited to the kidney  
T1b: Tumour more than 4 cm but not more than 7 cm in greatest dimension, and limited to the kidney 
T2 Tumour more than 7 cm in greatest dimension, limited to the kidney  
T2a: Tumour more than 7 cm but less than or equal to 10 cm in greatest dimension, limited to the kidney 
T2b: Tumour more than 10 cm, limited to the kidney 
T3 Tumour extends into major veins or perinephric tissues but not into the ipsilateral adrenal gland and not beyond 
Gerota's fascia  
T3a: Tumour grossly extends into the renal vein or its segmental (muscle containing) branches, or tumour invades 
perirenal and/or renal sinus fat but not beyond Gerota's fascia  
T3b: Tumour grossly extends into the vena cava below the diaphragm  
T3c: Tumour grossly extends into the vena cava above the diaphragm or invades the wall of the vena cava 
T4 Tumour invades beyond Gerota's fascia (including contiguous extension into the ipsilateral adrenal gland) 
REGIONAL LYMPH NODES (N) 
NX Regional lymph nodes cannot be assessed 
N0 No regional lymph node metastasis 
N1 Metastasis in regional lymph node(s) 
DISTANT METASTASIS (M) 
M0 No distant metastasis 
MI Distant metastasis 
Table 1: TNM staging system for kidney cancer 
 
STAGE TUMOUR LYMPH NODES METASTASES 
Stage I T1 N0 M0 
Stage II T2 N0 M0 
Stage III T1 or T2 N1 M0 
T3 N0 or N1 M0 
Stage IV T4 Any N M0 
Any T Any N M1 
Table 2: Anatomic staging/prognostic groups 
 
For localized resectable RCC, surgery can be curative in the majority of patients.  Forty percent will relapse with 
either local and/or metastatic disease (15)(16). When distant metastases occur, some patients with a limited 
amount of lesions could be cured with metastasectomy or local radiation therapy, but the majority will require 
systemic therapy.  
In patients with metastatic disease at initial diagnosis or locally advanced non-resectable disease, cytoreductive 
nephrectomy remains standard of care. With a response rate (RR) of only 5 to 10%, classical chemotherapy with 
cytotoxic drugs does not have an established role in the management of mRCC patients. Only subgroups of 
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patients can occasionally respond to chemotherapy and the quality of responses is usually poor. The introduction 
of immunotherapy with either interleukin-2 (IL2) or Interferon (IFN)-alpha slightly improved the outcome of mRCC 
patients through immune-modulatory effects. Immunotherapy with high-dose bolus IL2 results in tumour 
regressions in a minority (10%) of patients. Although this treatment is associated with severe toxicity, responses 
may persist for many years, even in the absence of additional therapy, and the majority of complete responders 
remain free of relapse for prolonged periods of time. Monotherapy with IFN-alpha in mRCC leads to RR in the 
range of 15%, most responses are partial and rarely persist beyond one year. Treatment with IFN-alpha is 
associated with an average median improvement in survival of four months (17).  
Over the last 10 years, molecularly targeted therapy directed against the VEGF-pathway has appeared on the 
scene with several new compounds such as the anti-VEGFR-TKIs sunitinib, sorafenib, pazopanib and axitinib and 
the monoclonal anti-VEGF-antibody bevacizumab. Moreover, two mTOR inhibitors, everolimus and temsirolimus, 
have also become available. These compounds have largely replaced the use of immunotherapy for patients with 
advanced RCC since 2005 because of demonstrated improved efficacy. Sunitinib and pazopanib are the most 
commonly used oral drugs for first-line anti-VEGF-targeted therapy for mRCC. Table 3 shows  the results of 
pivotal phase III trials that have established the efficacy of these compounds in kidney cancer. 
The efficacy of sunitinib in m-ccRCC was shown in a phase III trial of 750 patients with largely good or 
intermediate MSKCC prognosis who had not received any prior systemic therapy. Patients were randomly 
assigned to sunitinib or IFN-alpha. The RR was significantly increased with sunitinib (47 versus 12%) and median 
PFS (mPFS) was significantly prolonged (11 versus 5 months, p<0.001). OS was 26.4 months with sunitinib 
versus 21.8 months with IFN-alpha (p=0.051) (3, 18). In a phase III trial, 435 patients, with mainly clear cell 
histotype, good or intermediate MSKCC risk, who were previously untreated or had received only cytokine 
therapy, were randomly assigned to pazopanib or placebo. There was a significant increase in mPFS with 
pazopanib compared with placebo (9.2 versus 4.2 months, HR 0.46). Median OS (mOS) was non-significantly 
different (22.9 versus 20.5 months, HR 0.91), but these results are confounded by the high rate of cross-over 
and/or use of other treatments after initial evidence of progressive disease in patients included in the placebo arm 
of the trial (4). Two phase III trials compared sunitinib to pazopanib in first-line therapy. The first trial showed non-
inferiority of pazopanib in terms of PFS (19). The second, much smaller trial demonstrated patient preference for 
pazopanib in a randomized, double blind setting.   
In second-line setting, axitinib has been studied in a randomized phase III trial that included 723 m-ccRCC 
patients who had prior treatment with a cytokine (35%) or another anti-VEGF or mTOR-targeted treatment (54% 
with sunitinib, some with bevacizumab or temsirolimus). Compared to sorafenib, axitinib resulted in a significant 
improvement in mPFS (7 versus 5 months). The benefit in PFS was higher in patients previously treated with 
cytokines (12 versus 7 months) than in patients previously treated with sunitinib (5 versus 3 months). There was 
also a significant increase in RR (19 versus 9%) (20). 
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TRIAL INCLUDED 
PATIENTS 
PROGNOSTIC 
GROUPS (MSKCC) 
PFS 
(MONTHS) 
OS 
(MONTHS) 
RR EXPERIMENTAL 
ARM 
EFFICACY OF TARGETED THERAPIES IN PATIENTS PRE-TREATED WITH CYTOKINES 
Sorafenib versus placebo 
TARGET 
Clear cell Good 52% 
Intermediate 48% 
Poor 0% 
5.5 versus 2.8 
p<0.01 
 
17.8 versus 
15.2 
NS 
PR 10% 
SD 74% 
PD 16% 
Pazopanib versus placebo 
 
Clear cell (or 
predominantly) 
Good 39% 
Intermediate 55% 
Poor 3% 
7.4 versus 4.2 
p<0.001 
 
Cross-over PR 33% 
SD 42% 
PD 16% 
Axitinib versus sorafenib 
AXIS  
Clear cell Not available 12.1 versus 
6.5 
p<0.0001 
Cross-over  NR 
EFFICACY OF FIRST-LINE TARGETED THERAPIES IN TREATMENT NAIVE PATIENTS 
Sunitinib versus interferon 
 
Clear cell Good 38% 
Intermediate 56% 
Poor 6% 
11 versus 5.1 
 p<0.001 
 
26.4 versus 
21.8 
p=0.051 
CR 3% 
PR 44% 
SD 40% 
PD 7% 
Temsirolimus versus 
Interferon 
 
(Non) clear 
cell 
Intermediate 31% 
Poor 69% 
5.5 versus 3.1 
p<0.001 
10.9 versus 
7.3 
p=0.008 
 
CR 0% 
PR 9% 
SD 46% 
Bevacizumab+Interferon 
versus Interferon+placebo 
AVOREN  
Clear cell or 
clear cell 
component 
Good 29% 
Intermediate 56% 
Poor 8% 
10.2 versus 
5.5 
p=0.0001 
23.3 versus 
21.3 
NS 
CR 1% 
PR 30% 
SD 46% 
PD 20% 
Bevacizumab+Interferon 
versus Interferon+placebo 
CALGB 
Clear cell Good 26% 
Intermediate 64% 
Poor 10% 
8.5 versus 5.2 
p<0.0001 
18.3 versus 
17.4 
NS 
PR 26% 
Pazopanib versus placebo 
 
Clear cell or 
clear cell 
component 
Good 39% 
Intermediate 55% 
Poor 3% 
11.1 versus 
2.8 
p<0.001 
Cross-over 
 
PR 32% 
EFFICACY OF SECOND-LINE TARGETED THERAPIES IN PATIENTS PROGRESSING ON FIRST-LINE TKIs 
Everolimus versus 
placebo 
RECORD-1 
After TKI 
failure 
Clear cell 
component 
Good 29% 
Intermediate 56% 
Poor 15% 
4.0 versus 1.9  
p<0.0001 
 
Cross-over 
 
PR 1% 
SD 63% 
PD 36% 
Axitinib versus sorafenib 
AXIS 
Second-line 
after sunitinib 
Clear cell 
Not available 4.8 versus 3.4  
p=0.0107 
Cross-over 
 
Axitinib: PR 11.3%  
Sorafenib: PR 7.7% 
Table 3: Overview of phase III trials with targeted therapy for mRCC. NS: not significant. NR: not reported.  
 
The efficacy of sorafenib in advanced ccRCC was demonstrated in a phase III trial, in which 903 patients who had 
failed prior cytokine therapy were randomly assigned to sorafenib or placebo. mPFS was significantly longer in 
those receiving sorafenib compared with placebo (5.5 versus 2.8 months). mOS was not significantly prolonged 
(17.8 versus 15.2 months), but patients were allowed to cross-over and receive sorafenib, potentially obscuring 
survival differences (2, 21).   
Bevacizumab is a monoclonal antibody that binds circulating VEGF and prevents its interaction with the VEGFR. 
Two phase III trials randomized 649 and 732 previously untreated m-ccRCC patients in two treatment arms: 
bevacizumab plus IFN-alpha compared with IFN-alpha alone. In the first trial (22-25), the combination resulted in 
an increase in mPFS (10.2 versus 5.5 months), a significantly higher RR (31 versus 13%) and a trend toward 
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improved mOS (23.3 versus 21.3 months). The second trial reported similar results (26). In both studies, the 
survival analysis was biased by the fact that more than one-half of patients on both arms received second-line 
therapy, including VEGF-targeted therapy in those originally treated with IFN-alpha alone.  
The mTOR-pathway is downstream of the phosphoinositide-3-kinase and AKT-pathway that is regulated by the 
PTEN tumour suppressor gene. Inhibition of the mTOR-pathway by temsirolimus or everolimus has the potential 
to inhibit tumour progression at multiple levels. In randomized trials, the mTOR-inhibitors temsirolimus and 
everolimus have shown clinical activity in mRCC patients. Temsirolimus has shown efficacy in first-line MSKCC 
poor risk mRCC (5, 27) and everolimus in second-line therapy after progression on anti-VEGF-targeted therapy 
(6, 28) 
As a consequence, within 8 years, 7 compounds were approved for the treatment of mRCC. This raises questions 
regarding the optimal use of these agents, including which agent to use in a particular patient, what is the optimal 
sequence of available agents and if concomitant use of these therapies can lead to improved outcomes. Several 
trials investigated the combined use of agents hitting the VEGF- and the mTOR-pathway. These trials 
consequently led to increased toxicity, but not to increased efficacy. Concerning sequential use of these 
compounds, axitinib and everolimus are the two molecules with phase III data proving efficacy in patients who 
progressed on a first-line therapy with TKIs. Temsirolimus, sunitinib and sorafenib can also be given in second-
line. Nevertheless, the global efficacy of second-line therapy is rather disappointing, with shorter PFS, fewer PRs 
and no long lasting disease control in the vast majority of patients. Retrospective studies as well as a randomized 
phase III trial comparing sorafenib and temsirolimus after sunitinib did not show any advantage of switching to 
mTOR-inhibition compared to continuing a second anti-VEGF-targeted therapy (29).  
Surgery and radiation therapy may be used in carefully selected mRCC patients. Despite the characterization of 
RCC as a relatively radio-resistant tumour, conventional and stereotactic radiation therapy can be used to treat 
symptomatic bone lesions or brain metastases. The resection of a limited number of metastases can be 
considered in combination with nephrectomy or at subsequent relapse in carefully selected patients for both pain 
relief and tumour control. The reported outcomes after resection have been variable, with five-year survival in 
small series ranging from 13 to 50%. Selection bias has an important impact on such reported results.  
In patients qualifying for systemic therapy, immediate start of treatment or a watchful waiting policy can be 
considered. Some RCCs can have a very indolent course and spontaneous regression of metastasis is observed 
in individual patients. (30).  
 
2. PATHOPHYSIOLOGY OF CLEAR CELL RENAL CELL CARCINOMA  
 
ccRCCs arise from cells of the proximal tubule, either sporadically, or associated with three distinct cancer 
syndromes: the Von Hippel-Lindau (VHL) disease, hereditary paraganglioma and pheochromocytoma and 
tuberous sclerosis complex. The most common genomic alterations in ccRCC are loss of chromosome 3p and 
mutations in the VHL gene located on 3p25-26 or hyper-methylation of its promoter. The initial insights into the 
molecular pathogenesis of ccRCC came from studies in VHL-disease, where VHL-associated RCCs showed loss 
of heterozygosity (LOH) at the VHL-locus. 
VHL-disease is an inherited, autosomal dominant syndrome associated with a variety of benign and malignant 
tumours: haemangioblastomas of the cerebellum and spine, retinal angiomas, multiple renal cysts and ccRCCs 
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(in 66% of patients), pheochromocytomas, endolymphatic sac tumours of the middle ear, serous cystadenomas, 
neuroendocrine tumours of the pancreas and papillary cystadenomas of the epididymis and broad ligament. A 
VHL-gene abnormality is present in about 1 in 36.000 individuals. Affected patients have a germ-line mutation that 
inactivates one copy of the VHL-gene in all cells. For disease to occur there must be loss of expression of the 
second, normal allele (31).  
In sporadic ccRCC, VHL-gene inactivation occurs in approximately 60-70% of the cases, mostly through 
mutations (55-60%), but in 10-15% of cases through promoter hyper-methylation (32-35). In the majority of 
tumours that show somatic VHL-mutations, the other allele is deleted by LOH. Other reports using high 
throughput methodologies allowed to improve identification of VHL-alterations: up to 91% of patients with ccRCC 
patients harbour a VHL-gene alteration through genetic or epigenetic mechanisms (36). Moreover, introduction of 
a 3p chromosome fragment in ccRCC cell-lines suppresses tumorigenicity (37).  
VHL-gene inactivation seems to be an early event in ccRCC carcinogenesis. This is suggested by the frequency 
of this event and the fact that there is no link between mutational status versus hyper-methylation versus none of 
both and the clinical characteristics of the tumours.  
The VHL-protein controls the metabolism of HIF. Other functions of the VHL-protein are fibronectin assembly, 
microtubule stability, atypical protein kinase C activity and p53 regulation in an HIF-independent way (38). 
 
2.1. VHL inactivation leading to hyper-vascular tumours through hypoxia-inducible factor (HIF) induction 
 
HIF as a transcription factor and a key regulator of hypoxia-inducible genes regulates more than 100 genes, 
controlling angiogenesis, cell cycle induction, apoptosis, glucose metabolism, erythropoiesis,  macrophage 
function, extracellular matrix (ECM) remodelling, tumour growth factors and receptors and cell migration (39).  
HIF is a heterodimer consisting in an alpha subunit (HIF1-alpha or HIF2-alpha), sensitive to oxygen levels, bound 
by the VHL-protein, and a beta subunit (HIF1-beta or aryl hydrocarbon receptor nuclear translocator), not 
influenced by the oxygen tension and not bound by the VHL-protein complex. Under normoxic conditions, HIF1-
alpha is hydroxylated which creates a binding site for the VHL-protein leading to an E3-ubiquitin ligase-mediated 
degradation in the proteasome. In the presence of oxygen, the half-life of HIF1-alpha is less than 5 minutes.  
Under hypoxic conditions, there is no HIF hydroxylation and hence no ubiquitination and no degradation. The 
combination of HIF1-beta and HIF1-alpha or HIF2-alpha becomes a transcription factor that accumulates in the 
nucleus and binds on hypoxia responsive elements inducing the transcription of numerous genes as a physiologic 
response to hypoxia. Nevertheless, once this physiologic response has restored normoxia in the tissue, HIF will 
be degraded again by the VHL-protein. In case of loss of VHL-protein function, HIF cannot be degraded anymore 
and the downstream HIF dependent genes will remain up-regulated even in restored normoxic conditions.  
HIF is clearly up-regulated in tumours with VHL-loss. In one study, increased expression of HIF was recorded in 
75% of ccRCC and only 38% of non–ccRCC cases (40). In another study, the level of HIF appeared to correlate 
with the presence of VHL-mutation and none of the HIF-negative ccRCC patients showed a mutation of the VHL-
gene. ccRCC had a significantly higher HIF-expression compared to papillary or chromophobe RCC variants (41). 
HIF induces cellular multiplication through three pathways: (A) activation of c-myc, which induces the cell cycle by 
the activation of cyclin-D2 and E2F1 and the repression of p21 and p27, (B) c-myc mediated mismatch repair, 
which is necessary to compensate for replication stress in high turnover cells, (C) transcription of growth factors 
and receptors like epithelial growth factor receptor (EGFR) (expressed on RCC cells) and its ligand transforming 
16 
 
growth factor (TGF)-alpha, chemokine-CXC-motif-receptor-4 (CXCR4) (expressed on RCC cells) and its ligand 
stromal derived factor-1 (SDF1), insulin-like growth factor (ILGF) and its binding protein and TGF-beta. The over-
expressed and activated CXCR4 and EGFR will activate the RAS/RAF/ERK/MAPK1 pathway, leading to cell 
cycle induction, and the RAS/Pl3K/PDK/AKT/mTOR-pathway, leading to HIF-activation.  
HIF promotes neo-angiogenesis by activating several genes: VEGF and its receptor VEGFR1, -2 and -3, PDGF 
and its receptors PDGFR-alpha and -beta, fibroblast growth factor (FGF)-2 and FGF5, angiopoietin-2 (ANG2) and 
its receptor Tie2, plasminogen activator inhibitor-1, SDF1 and hepatocyte growth factor (HGF). HIF also induces 
several genes linked to glucose transportation and metabolism, necessary for energy delivery to multiplying cells, 
as well as invasiveness genes, like matrix metalloproteinases (MMPs). MMPs are necessary for normal 
angiogenesis, because they have to cut the basal membrane allowing the penetration of new vessels. This 
rupture of the basal membrane will also permit cell migration into the blood circulation, thus promoting metastasis 
in case of cancer. 
In case of VHL-protein dysfunction, restored normoxia will not lead to HIF-degradation and HIF will pursue its 
activity that will even become auto-reinforcing through an autocrine loop. Moreover, due to insufficient neo-
angiogenesis and uncontrolled cellular growth, there will be enhanced interstitial pressure and vascular 
compression, which will again lead to hypoxia and HIF-activation. These auto-reinforcing loops are probably at 
the origin of uncontrolled cellular multiplication and thus tumorigenesis. Adding neo-angiogenesis, enhanced 
glucose transportation and rupture of the basal membrane by MMPs, all the conditions for tumoral growth and 
metastasis are fulfilled.  
Of note, HIF can also be activated in cancer by micro-environmental hypoxia in hypoxic tumour zones, without 
VHL silencing (42). 
 
2.2. HIF1-alpha and HIF2-alpha subtypes 
 
HIF1-alpha and HIF2-alpha have overlapping effects on angiogenesis and ECM remodelling, but distinct effects 
on cell metabolism and proliferation. HIF1-alpha activates the transcription of the MXI1-gene, which encodes a 
repressor of c-myc transcriptional activity, and promotes a MXI-1-independent proteasome dependent 
degradation of c-myc  (43, 44). Cyclin D is down-regulated by HIF1-alpha. HIF1-alpha enhances transcription of 
BNIP3, a BCL2-related promoter of apoptosis. As a consequence, HIF1-alpha opposes cell cycle progression, 
induces cell arrest and opposes c-myc mediated mismatch repair. Glucose-transporter protein-1 (GLU1), a 
regulator of glucose metabolism, is down-regulated by HIF1-alpha (45).  
HIF2-alpha induces the c-myc oncoprotein and c-myc mediated expression of cyclin-D2, cyclin-G2 and E2F1 and 
thus cellular proliferation. HIF2-alpha enhances DNA-mismatch repair and the expression of TGF-alpha, inducing 
an autocrine loop targeting the EGFR, MMP, GLU1, ANG2 and its receptor Tie2 and VEGF (42, 46). BNIP3 is 
down-regulated by HIF2-alpha (45). 
This differential transcriptional activity of HIF1-alpha and HIF2-alpha attributes more aggressive genes to the 
influence of HIF2-alpha and confirms its important role in tumorigenesis. The HIF2-alpha subunit is primarily 
responsible for the growth of VHL-deficient human ccRCC xenografts. siRNA-mediated down-regulation of HIF2-
alpha suppresses tumour formation by VHL-defective RCC cells (47). Finally, in a series of 160 tumours, not any 
tumour expressed HIF1-alpha without HIF2-alpha, strongly suggesting that HIF2-alpha is critical for the 
development of VHL-deficient ccRCC (48).  
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2.3. Neo-vascularisation in mRCC 
 
When a tumour or a metastasis grows and cells in the centre of the tumour mass become hypoxic, the tumour 
initiates recruitment of its own blood supply, by shifting the balance between physiological angiogenesis inhibitors 
and stimulators towards the latter, a process called "angiogenic switch".  
ccRCC are among the most hyper-vascular tumours in which pro-angiogenic mechanisms such as the VEGF- 
and/or other pro-angiogenic pathways are hyper-activated (Figure 1). On pathological analysis, ccRCC have 
significantly higher micro-vessel counts than non-ccRCC and these counts are correlated with the level of VEGF-
expression (42). Enhanced VEGF-concentration occurs in RCC patients with VHL-gene alterations and advanced 
grade (49, 50). 
       
         
Figure 1. Contrast enhanced arterial phase CT of two patients with metastases from ccRCC. The liver 
metastasis at the left and soft tissue metastasis at the right display contrast enhancement due their high 
level of vascularization.   
 
2.4. VEGF, the dominant growth factor controlling angiogenesis 
 
Although there are multiple pro-angiogenic factors, the dominant growth factor controlling angiogenesis is VEGF 
(50, 51). VEGF-expression is highly regulated by hypoxia, providing a feedback mechanism to accommodate 
reduced tissue oxygenation via the promotion of new blood vessel formation. VEGF, produced by a number of 
different cell types, acts selectively on vascular endothelial cells, and is capable of stimulating angiogenesis in 
vitro and in vivo. It plays an active role in the induction, maintenance, and growth of vascular endothelial cells. 
VEGF also controls vascular permeability and is 50.000 times more potent in inducing vascular leakage than 
histamine. VEGF stimulates expression of tissue plasminogen activator, urokinase plasminogen activator, 
collagenases, and MMPs, involved in the degradation of the ECM, required for endothelial cell migration.  
VEGF mediates angiogenic signals to the vascular endothelium via high affinity receptor tyrosine kinases, 
designated VEGFR1, -2, and -3. These receptors are expressed almost exclusively on endothelial cells. 
Neuropilin-1 has been proposed to function as a VEGFR2-co-receptor capable of enhancing the biological effects 
of VEGF on endothelial cells. Tip cells, which are the cell at the leading edge of an angiogenic sprout, are 
primarily responsible for sensing the chemo-attractive VEGF-gradients secreted by hypoxic tissue. The tip cells 
express high levels of VEGFR3 (50). 
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Neo-angiogenesis occurs in an activation and a maturation phase. The activation phase implies the destruction of 
the basal membrane around the existing vessel by MMPs, the recruitment, migration and proliferation of 
endothelial cells under influence of VEGF, the formation of a primitive tube of endothelial cells and the connection 
to existing vessels. Bone marrow-derived haematopoietic cells expressing markers such as CXCR4 and/or 
VEGFR1 become recruited, often together with endothelial progenitor cells, to tumours or ischaemic tissues in 
response to VEGF and placenta like growth factor (PlGF). The maturation phase leads to the stabilization of the 
developing vascularization by the reconstruction of a basal membrane and the recruitment of perivascular cells 
(pericytes) that will cover the new formed vessels. These mural cells differentiate from perivascular progenitor 
cells, which are mobilized from the bone marrow in response to PDGF-beta.  
The VEGF-signalling pathway seems to be over-expressed early during ccRCC pathogenesis. In tumours, in 
contrast to other tissue, VEGF is not produced by the endothelial cells, but by tumour cells or stroma, consistent 
with a paracrine mode of action. When PDGFs are over-expressed, tumour vessels are covered by more mural 
cells and tumour growth is accelerated. 
 
 
 
Figure 2. The involvement of VHL-dysfunction in the pathogenesis of ccRCCs and the resulting 
therapeutic targets. In conditions of normoxia and normal VHL-gene function, VHL-protein leads to the 
continuous degradation of HIF-alpha. In cellular hypoxia or with an inactivated VHL-gene, the VHL 
protein–HIF interaction is disrupted, leading to stabilization and accumulation of HIF transcription factors 
and the subsequent transcription of a large range of hypoxia-inducible genes, including VEGF and PDGF. 
These ligands bind to their receptors present on the surface of endothelial cells, leading to neo-
angiogenesis. HIF also induces cell cycle through the induction of cyclin D1 and c-myc. The VEGF-
activation can be blocked with the monoclonal anti-VEGF-antibody bevacizumab of with the anti-VEGFR-
TKIs sunitinib, sorafenib, axitinib or pazopanib. Courtesy of Rini et al. and reproduced with permission 
from The Lancet Oncology. Copyright owned by Elsevier Ltd (7). 
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2.5. Other frequent mutations in ccRCC 
 
Several other mutations have been described in ccRCC: PBRM1 (in 41% of cases), BAP1 (8-15%), FAM123B 
(13%), CTNNB1 (16%), WT1 (11%), CDKN2A (7-10%), p53 (8%), UTX (KDM6A) (1.4-3%), SETD2 (3-4%), 
JARID1C (KDM5C) (3-9%), NF2 (5%) and PTEN (4%). Interestingly, several of these genes (PBRM1, BAP1, 
SETD2) are located on 3p and involved in chromatin organisation. Moreover, VHL and BAP1 are members of the 
ubiquitin-mediated proteolysis pathway (UMPP), an important pathway for protein degradation through the 
proteasome. Alterations in genes encoding UMPP are associated with overexpression of HIF, even in the 
absence of VHL-mutation, thus they result in similar functional consequences as VHL-inactivation. In one study, 
UMPP was the most frequently altered pathway in ccRCC (51). 
Polybromo-1 (PBRM1) is the second most mutated ccRCC gene, with truncating mutations in 41% of cases (52). 
PBRM1 is likely a tumour-suppressor gene. PBRM1 maps to chromosome 3p21 and encodes the BAF180 
protein, the chromatin targeting subunit of the PBAF Switch/Sucrose Non Fermentable SWI/SNF chromatin 
remodelling complex (53). PBAF complex-mediated chromatin remodelling is implicated in replication, 
transcription, DNA repair and control of cell proliferation and differentiation. PBRM1 activity regulates pathways 
associated with chromosomal instability and cellular proliferation. The SWI/SNF complex has been implicated in 
the normal cellular response to hypoxia, with impairment of the complex rendering cells resistant to hypoxia-
induced cell cycle arrest (54).   
The BRCA1 associated protein-1 (BAP1), located at 3p, is a nuclear deubiquitinase part of the large UMPP (55). 
BAP1-mutant tumours are more likely to be aggressive and display adverse pathologic features, such as high 
Fuhrman grade, sarcomatoid and rhabdoid features of RCC, tumour necrosis, and mTOR Complex-1 activation. 
BAP1-mutant tumours are associated with changes in the expression of genes implicated in growth-factor 
signalling. Most genes that make up the BAP1 signature are down-regulated in BAP1-mutant tumours. This raise 
the possibility that in the absence of BAP1 transcription factors are ubiquitinated and targeted for proteosomal-
mediated degradation. BAP1 and PBRM1-mutations are mutually exclusive. mOS is significantly shorter for 
patients with BAP1-mutant tumours than for patients with PBRM1-mutant tumours and tumours exclusively 
mutated for PBRM1 tend to be of lower grade (56). 
SETD2 and JARID1C, in which the mutations are inactivating, encode enzymes involved in histone modification 
through demethylation, highlighting the important role of components of the chromatin modification machinery in 
RCC (57, 58). Sato et al. reported a poorer disease-free survival in patients with SETD2-mutated tumours (59). 
VHL-mutations or loss of the VHL-function seem to be an early event in ccRCC pathogenesis, but not sufficient 
for the development of a tumour. Additional events are warranted. Mice bearing a VHL-mutation do not develop 
more often RCCs than the non-mutated counterparts. This is probably explained by the fact that in mice, BAP1 
and PBRM1 are located on other chromosomes than VHL (60, 61). Both BAP1 and PBRM1 are two-hit tumour 
suppressor genes and they are located on chromosome 3p. The hypothesis is that, in many instances, the 
development of ccRCC is initiated by a focal mutation in VHL, followed by a 3p deletion. 3p loss may eliminate 
VHL-gene function and would leave cells with just one copy of BAP1 and PBRM1. Mutation of the remaining 
BAP1 or PBRM1 allele may initiate tumorigenesis, resulting in tumours of different aggressiveness, depending on 
which gene is mutated. Thus, tumour aggressiveness may be established early on during the process of 
tumorigenesis (56). 
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2.6. Cytogenetic abnormalities, intratumoral heterogeneity, and ccRCC-subgroups based on expression 
profiles 
 
In ccRCC, besides quasi omnipresent loss of 3p, there is a frequent gain of 5q (69% of cases), 7q (20-30%) and 
8q (12%) and monosomy or partial loss of 14q (42%), 8p deletion (32%) and 9p loss (29%) (62).  
There is evidence for significant intratumoral heterogeneity concerning frequently observed mutations in RCC. 
Differences in the mutational status can be found within one tumour or when comparing the original tumour with 
the metastases. Nevertheless, ubiquitous allelic-imbalance events were seen on chromosome 3p (encoding VHL, 
PBRM1, BAP1 and SETD2), 5q, 6q and 10q (63).  
Recently, important progress has been made in the identification of subgroups of ccRCCs through the analysis of 
gene-expression profiles and the additional analysis of epigenetic, cytogenetic and mutational characteristics of 
these tumours. In a series of 225 ccRCC, using traditional unsupervised gene expression analysis in a two-step 
analysis, with hybridization in a first group of samples, and validation by quantitative qRT-PCR on a second group 
of samples, Brannon et al. described two molecular sub-classifications of ccRCCs, called ccA and ccB (64). Both 
subgroups were confirmed in a meta-analysis of publicly available expression profiles of 480 ccRCCs, with the 
identification of an additional third group, called Cluster_3, and associated with a VHL wild-type profile (65). 
Brannon’s ccA-tumours (51% of cases) showed overexpression of genes associated with hypoxia, angiogenesis, 
the beta-oxidation pathway, fatty acid metabolism, pyruvate metabolism, and organic acid metabolism. ccB-
tumours (36% of cases) over-expressed a more aggressive panel of genes that regulate cell differentiation, 
epithelial-to-mesenchymal transition (EMT), the mitotic cell cycle, TGF-beta, wound healing and WNT. In ccB- 
tumours angiogenesis, beta-oxidation, pyruvate metabolism and organic and fatty acid metabolism were 
downregulated. ccB-tumours were more often Fuhrman grade 4. HIF signalling was found to be over-expressed in 
ccA relative to ccB tumours, although VHL-inactivation was observed by Brannon et al. in both clusters. Cluster_3 
tumours (13% of cases) were characterized by over-expression of mitochondrial bioenergetics pathways and 
down-regulation of hypoxia and angiogenesis pathways. Histology was found to be reported ambiguously in this 
subgroup. More recently, four subgroups of ccRCCs and their associations with copy number abnormalities, 
epigenetic and mutational characteristics, were described by the TCGA-project (66) and by Sato et al. (59).  
 
3. MECHANISM OF ACTION OF ANTI-ANGIOGENIC DRUGS 
 
In order to understand the mechanisms of resistance to VEGF-targeted therapy, we should first understand the 
mechanisms of action of these therapies.  
 
3.1. Inhibition of the VEGF- and PDGF-pathway 
 
Anti-VEGFR-TKIs are thought to exert their major therapeutic effects in RCC by antagonising the VEGF-pathway, 
leading to reduced tumour angiogenesis (67). This concept is based largely on the significant up-regulation of 
VEGF in ccRCC as a result of VHL-inactivation, and the finding of anti-angiogenic effects in preclinical models 
(68-71). Moreover, anti-VEGF-targeted therapy is less efficient in non-ccRCCs (72-74), which are not associated 
with VHL-dysfunction.  
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Sunitinib, pazopanib, sorafenib and axitinib are orally available ATP-mimetic small molecule TKIs with tropism for 
the ATP-binding site of the VEGFR1, -2 and -3, although the specific affinity for these three receptors is variable. 
These compounds act as inhibitors of VEGFR signalling (75). The anti-VEGF-monoclonal antibody bevacizumab 
has a different mechanism of action: it captures circulating VEGF.  
Additionally, several anti-VEGFR-TKIs block the PDGF-pathway: sunitinib and pazopanib through inhibition of 
both the PDGFR-alpha and -beta and sorafenib through the inhibition of PDGFR-beta. PDGFR-inhibition might 
enhance the anti-angiogenic effects of anti-VEGFR-TKIs by targeting pericytes, which are able to protect 
endothelial cells from apoptosis in the setting of VEGFR-blockade. Under anti-VEGFR-TKI-treatment, fewer 
pericytes are recruited, tumour vessels are dilated, endothelial cell apoptosis is increased, angiogenesis is 
suppressed, the interstitial fluid pressure is lowered and drug delivery improves (76).  
 
3.2. Reduction of existing vessels, inhibition of new vessels and vessel normalization 
 
The anti-tumour effects of VEGF-inhibition have been ascribed to the observed reductions in tumour micro-vessel 
density and tumour blood flow. Anti-VEGF-targeted therapies arrest endothelial cell proliferation, prevent vessel 
growth and induce regression of existing vessels by increasing endothelial cell death. They also suppress the 
mobilization of endothelial progenitor cells from the bone marrow and lower vessel permeability and thus tumour 
interstitial pressure. 
VEGF-blockade as monotherapy has been clearly shown to have a direct and rapid anti-vascular effect in both 
animal and human tumours (77).  
In RCC xenograft models, immunohistochemistry (IHC) analysis of tumours resected shortly after starting 
treatment with sorafenib showed a characteristic pruning of the microvasculature with necrosis. This 
devascularisation was visualised by arterial spin labeling (ASL) perfusion magnetic resonance imaging (MRI), 
showing a prompt and nearly complete cessation of blood flow shortly after initiation of sorafenib (Figure 3.1. and 
3.2.) (71).  
 
Figure 3.1.: ASL MRI shows decreased perfusion on day 3. Courtesy of Schor-Bardach et al. (71) 
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Figure 3.2.: CD34 stain: Decrease of endothelial cells (arrows) on day 3. Courtesy of Schor-Bardach et al . 
(71) 
 
Under anti-VEGFR-targeted therapy, vessels diminish in quantity, but improve in quality. Pries et al. observed that 
VEGF-blockade resulted in a temporary and paradoxical "normalization" of tumour vasculature, with selective 
pruning of poorly formed vessels and a resulting temporary improvement of blood flow and oxygen delivery to the 
tumour (78). In papillary RCC xenografts in mice treated with sunitinib for 7-18 days, dynamic contrast-enhanced 
MRI performed after treatment showed increased perfusion and decreased vascular permeability. Histology 
showed thinning and regularization of tumour vessels (79).  
 
3.3. Multi-target TKIs: targeting other growth factor pathways as well as VEGF-independent angiogenesis 
 
Most of these small TKIs lack specificity and are therefore called multi-target TKIs. These broader substrate 
specificities may also complicate ascribing their action to purely anti-angiogenic mechanisms, both within the 
endothelial cell and the tumour cell itself. Sunitinib also blocks rearranged during transcription (RET), c-KIT, fms-
related tyrosine kinase 3 (FLT3) and FSC-1R. Pazopanib blocks C-FMS, LCK, ITK, KIT and FGFR1 and -3. 
Sorafenib blocks RET, FLT3, c-KIT, FGF-receptor-1 (FGFR1), C-RAF as well as wild type and mutant B-RAF. 
RAF kinase is an important mediator of the RAS/RAF/MEK pathway. Although activating mutations in B-RAF 
have not been identified in RCC, constitutive activation in the B-RAF pathway (RRAF, MEK, and ERK) has been 
observed in approximately 50% of tumours (40). As a consequence, the anti-tumour effects of sorafenib may be 
due to off-target effects on cyclin D1, cyclin B1, survivin and other key regulatory proteins (80).  
Moreover, tumour cells can express VEGFR1 and -2, Neuropilin1, PDGFR, FGFR, EGFR and receptors for other 
angiogenic factors. Hence, anti-VEGFR-targeted therapy could even have a direct cytotoxic effect.  
Finally, an immunomodulatory function of TKIs is also possible. As VEGFR1 suppresses dendritic cell function, 
anti-VEGF-targeted therapy might stimulate the function of dendritic cells and improve the natural anti-tumour 
immune response.  
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4. MECHANISMS OF RESISTANCE TO ANTI-ANGIOGENIC DRUGS 
 
4.1 Pharmacokinetic concerns: inadequate target inhibition due to reduced drug levels  
 
All anti-VEGFR-TKIs are administered at a fixed dose. Nevertheless, individual patient characteristics such as 
differences in absorption, excretion and metabolism as well as drug interactions may influence TKI-serum levels 
and as a consequence the efficacy of the treatment. Reduced drug plasma concentrations could lead to the 
development of resistance, or, more accurately, inadequate inhibition of VEGFR-signalling. Moreover, although 
these findings remain controversial, several publications showed a link between adverse events on TKIs (like 
hand-foot-syndrome, hypothyroidism and hypertension) and TKI efficacy, an association that could possibly be 
explained by higher exposure. As a consequence, monitoring drug concentrations to ensure adequate dosing 
would be of particular interest and could lead to more effective VEGF-pathway blockade through dose 
adaptations in patients with suboptimal TKI-plasma levels.  
After absorption, sunitinib is converted to an equipotent metabolite, SU12662. Since SU12662 has a similar 
inhibitory profile to sunitinib in preclinical assays, the combination of sunitinib plus SU12662 represents the total 
active drug in plasma. Both sunitinib and SU12662 are metabolized predominately by cytochrome P450 CYP3A4, 
and elimination is primarily via the faeces (81). The pharmacokinetics of both compounds are significantly 
influenced by several covariates including gender, age, and weight. However, in one pharmacokinetic study the 
magnitude of the predicted changes in exposure minimized the necessity for dose adjustments (82).  
Nevertheless, a clear association between sunitinib plasma levels and outcome has been observed: patients with 
the highest exposure to sunitinib displayed greater tumour size decreases and longer time-to-tumour-progression 
(TTP) and OS. There was a significant relationship between exposure and the probability of achieving a PR or 
complete response (CR) in mRCC patients. Thus, this analysis highlights the importance of maintaining patients 
on the maximal tolerated dose as long as possible and striving to avoid unscheduled dosing interruptions or 
titration during treatment.  
 
             
Fig. 5.1.: Relationship between average daily exposure (mean daily area under the curve (AUC) at steady 
state, AUCss) to sunitinib and TTP/OS. Courtesy of Houk et al. (83)  
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Fig. 5.2.: Probability of a partial or complete response (by RECIST criteria) versus average daily exposure 
(mean daily AUC at steady state, AUCss) to sunitinib. Lines represent model prediction and shaded area 
represents 95% confidence interval. Courtesy of Houk et al. (83) 
 
Moreover, in this study, the variability in clearance produced similar exposure ranges across the doses. The 
starting dose in all patients was 50 mg/day. This dose was adapted during treatment in function of tolerance. Final 
doses ranged from 25 to 75 mg/day. Nevertheless, the final plasma levels were nearly identical in all patients 
(83). 
 
Fig. 6.: Average daily exposure (mean daily AUC at steady state, AUCss) to sunitinib and total drug 
(sunitinib + its active metabolite SU12662) calculated at each patient’s final dose level. Courtesy of Houk 
et al. (83) 
 
Moreover, in a randomized phase II study, 213 patients were treated with axitinib 5 mg twice daily for four weeks, 
after which eligible patients (who did not experience grade 3/4 axitinib related toxicities and no hypertension) were 
randomly assigned further treatment with axitinib dose titration (stepwise from 5 to 7 to 10 mg twice a day based 
on tolerability) or axitinib with placebo dose titration. Patients who did not meet eligibility criteria were treated in a 
separate arm (axitinib ≤5 mg twice daily without dose titration). Among all patients, the mPFS was 14.5 months 
and RR was 48%. A higher axitinib exposure was associated with a higher RR (59 versus 40%) and an 
improvement in PFS (14 versus 11 months) (91). 
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4.2. The evidence of the angiogenic escape under VEGFR-blockade 
 
New imaging techniques support the idea that revascularisation is linked to resistance to VEGF-blocking therapy, 
a concept called “angiogenic escape”. After rapid lowering of tumour blood flow and normalization of the blood 
vessels at onset of therapy, a subsequent increase of the number of blood vessels and of the blood flow can 
announce progression.  
In RCC xenograft models, the development of resistance is consistently preceded by restoration of blood flow, as 
determined by perfusion scanning and by histology showing infiltration of the necrotic tumour remnant by 
endothelial cells (71).  
 
 
 
Figure 7.1.: ASL MRI shows decreased signal on day 3 with return of peripheral signal from Day 9 to 22. 
Courtesy of Schor-Bardach et al. (71) 
 
Figure 7.2.: CD34 stain: Viability and vessels correlated to new ASL MRI signal on day 9 and 22. Arrows 
show endothelial cells. Courtesy of Schor-Bardach et al. (71) 
 
In mRCC patients treated with vatalanib, an experimental anti-VEGFR-TKI, tumour blood flow after 1 month 
therapy, as assessed by ASL MRI, was positively correlated with size changes at 4 months. Changes in tumour 
perfusion at 1 month (increase or decrease) were a better predictor of PFS than RECIST-defined measurements 
of tumour size (84).  
These observations suggest that persistence or re-emergence of vasculature is relevant to resistance to anti-
VEGFR-TKIs. This re-establishment of vasculature can be less dependent, but not necessarily independent, of 
VEGF. 
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4.3. Inadequate target inhibition due to enhancement of the HIF-VEGF-pro-angiogenic pathway 
 
During treatment with anti-VEGFR-TKIs, tumoral hypoxia could increase leading to increase of HIF and 
subsequent enhanced transcription of the targets of HIF, among them genes involved in the VEGF-dependent 
angiogenesis pathway. In case of elevation of the VEGF-levels, the VEGF-blockade could become insufficient 
leading to angiogenic escape. Several experiences seem to strengthen this hypothesis.  
An up-regulation of circulating VEGF-levels during VEGFR-blockade with sorafenib was observed in the sorafenib 
RCC registration trial. Patients treated with placebo did not have an increase in circulating VEGF-levels (21, 85). 
Similarly, an increase in VEGF-levels in patients treated with sunitinib was found (86). These increasing VEGF-
levels under anti-VEGFR-TKI treatment could also explain some cases of rapid progression once anti-angiogenic 
therapy is stopped with the rapid formation of new vessels (87). 
The persistent, albeit less pronounced, efficacy of VEGF-pathway blockers after the development of resistance to 
an initial VEGFR-blockade, suggest that a component of the tumour remains dependent on VEGF and that this 
resistance can be countered by an improved VEGF-blockade. The level of tumour susceptibility might depend on 
features of previous VEGF-targeting drug exposure, including the relative potency of each agent against VEGFR.  
The efficacy of sorafenib in patients progressing after sunitinib was assessed in a phase II study and objective 
responses to sorafenib were observed in 5 of 52 patients (10%), with a median TTP (mTTP) of 16 weeks (88).  
In a randomized phase II trial with sorafenib, 43 (66%) of 65 patients who progressed on sorafenib 2x400mg/d 
had their dose escalated to 2x600mg/d. Forty-two percent of patients had a reduction in tumour size, although no 
objective responses according to RECIST were noted. mPFS was 3.6 months for patients escalated to sorafenib 
2x600mg/d (89).  
 
Axitinib, an anti-VEGFR-TKI with high potency to block VEGFR2, was assessed in a phase II trial in patients with 
mRCC, all of whom were refractory to sorafenib (77%) or sunitinib (23%). Fourteen of 62 patients (23%) achieved 
a PR. mPFS was 7.4 months and mOS 14 months. Tumour shrinkage was noted in 80% of patients (90). In a 
phase III trial, axitinib was studied against sorafenib in ccRCC patients who were progressive on one previous 
therapy line, mostly cytokines (35%) or sunitinib (54%). In patients who received sunitinib in first-line, mPFS was 
4.8 months for axitinib (n=194) and 3.4 months for sorafenib (n=194). The RR was 11.3% in patients treated with 
axitinib and 7.7% in patients treated with sorafenib (20).  
 
4.4. Up-regulation of alternative VEGF-independent angiogenesis 
 
Although there is abundance of HIF-enhanced pro-angiogenic factors besides VEGF- and PDGF-dependent 
angiogenesis, the VEGF-signalling pathway seems to be early over-expressed in ccRCC pathogenesis. As a 
consequence, VEGF-blockers could stop the whole angiogenesis in some ccRCC. Nevertheless, in a later 
disease stage, or in case of an efficient blocking of the VEGF-signalling pathway, the other pro-angiogenic factors 
can be responsible for further vessel growth.  
In late-stage pancreatic islet tumours in mice, unless efficient VEGF-blocking, neo-angiogenesis starts again 
under influence of other pro-angiogenic factors such as the FGF. VEGFR2-blockade with a neutralising 
monoclonal rat anti-VEGFR2-antibody induced an initial 50% reduction in tumour size and microvessel density 
that was inevitably followed by tumour regrowth, despite sustained VEGFR2-dephosphorylation in the tumour 
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endothelium. In the latter phase, there was tumour progression, re-induction of angiogenesis and reestablishment 
of the typically dense and aberrant tumour vasculature. The concurrent administration of an adenovirus encoding 
a soluble form of FGFR2 (which binds many members of the FGF-family) decreased tumour regrowth and 
revascularisation, implicating members of the FGF-family as the crucial growth factors responsible for VEGF-
independent tumour growth in this model (91). In another study, several members of the FGF-family of pro-
angiogenic factors were up-regulated during a VEGFR2-blocking treatment (92).  
IL8 is an alternative VEGF-independent pro-angiogenic growth factor. IL8 can enhance tumour angiogenesis in a 
setting in which VEGF production is impaired, and might have a similar role in circumstances in which VEGF is 
rendered less relevant due to drug-mediated receptor blockade. IL8-mediated angiogenesis was identified as a 
key compensatory mechanism of resistance to sunitinib in murine models of RCC. An anti-IL8 antibody did not 
affect tumour growth in xenograft-bearing animals not yet exposed to an anti-VEGFR-TKI, but after development 
of resistance to sunitinib, the combination of sunitinib and an anti-IL8 antibody efficiently reduced tumour growth. 
In addition, IL8-expression has been observed to be elevated in RCC tumours from patients refractory to sunitinib 
treatment (93). 
Considerable evidence suggests that the ANG2/Tie2-axis has angiogenic potential that could parallel the VEGF 
axis. In preclinical studies, inhibition of ANG2 led to suppression of tumour growth (94). ANG2-levels rise in the 
plasma of patients at the time of resistance to sunitinib. Therefore, ANG2-inhibition could prevent the 
revascularisation of tumours at the time of resistance.  
 
4.5. Other mechanisms of escape 
 
In most cases, tumoral regrowth is preceded by neo-angiogenesis. In other cases, relapsing metastases do not 
display contrast enhancement on imaging, thus no important neo-vascularisation. In these cases, tumour 
regrowth seems to be independent of neo-angiogenesis and could be the consequence of the activation of new 
pathways inducing cell growth such as EMT.  
One concern of anti-VEGF-targeted therapy in ccRCC is that in contrast to c-kit inhibition in bcl-abl mutated 
chronic myeloid leucemia or GIST, VEGF-blocking agents are not blocking an activating mutation, but acting far 
downstream the initial dysregulated site, which is the metabolism of HIF. By blocking VEGF- and PDGF-
pathways, we are in most cases even not acting directly on the tumoral cells, but only on the endothelial cells and 
pericytes. The other genes over-expressed by HIF and involved in tumour growth and invasiveness, are not 
directly blocked by VEGFR- and PDGFR-targeted therapy, unless indirectly through down-regulation of HIF-levels 
through decrease of tumoral hypoxia. 
Several signalling pathways involved in neo-angiogenesis and cell cycle induction can be up-regulated in RCCs 
leading to enhanced tumour growth. The mTOR-pathway seems to play a central role in this up-regulation. In 
RCC as well as in other tumour types, the mTOR-pathway is activated, although rarely through activating 
mutations. Inhibition of the mTOR-pathway through mTOR-inhibitors produces a modest anti-tumoral activity in 
RCC as well as in pancreatic neuro-endocrine tumours and in breast carcinoma (5, 6).  
EMT is a reversible process through which normal cells or cancer cells lose their epithelial characteristics and 
acquire a mesenchymal phenotype. Through EMT, these cells acquire a spindle shape and exhibit a more 
aggressive behaviour with enhanced invasiveness, increased metastatic spread and hypoxia-resistance. EMT 
can be induced by hypoxia and possibly by anti-VEGFR-targeted therapy. In hepatocellular carcinoma, after long-
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term exposure to sorafenib, resistant cells changed morphologically into spindle shaped cells and showed loss of 
cell-to-cell contacts, which are typical features of EMT (95). 
Other preclinical data have even raised the possibility that angiogenesis inhibitors might in fact reduce primary 
tumour growth while at the same time inducing tumour adaptation and progression to greater degrees of tumour 
invasiveness and metastatic behaviour (96-98). These findings may help to explain the development of resistance 
to these agents, but their relevance to clinical use of angiogenesis inhibitors in patients with cancer is as yet 
unknown. Moreover, these effects were observed in  pancreatic island tumours in mice and not in RCC (99). 
Another mechanism of escaping hypoxia could be new ways of proliferating of the tumours like lymphangitis 
carcinomatosa. A tumour will normally form spheres, but in lack of oxygen supply, the tumoral cells will rather 
proliferate along existing blood vessels, where more oxygen is available. Intratumoral heterogeneity could 
probably also lead to therapeutic resistance, although targeting ubiquitous events will have a global effect on all 
metastatic sites (64). 
 
4.6. Arguments against intrinsic resistance 
 
There are several reasons to believe that resistance to VEGF-targeted therapy is in most cases not induced by 
secondary mutations. Mutation in a gene encoding for a key receptor kinase is an unlikely explanation for the 
development of resistance to VEGF-pathway antagonists. The main target for VEGFR-inhibitors resides on 
endothelial cells. A mutation conferring treatment resistance would probably need to occur in the tumour 
endothelium, presumably in the gene encoding VEGFR2. The simultaneous occurrence of such a mutation in the 
endothelium of each individual tumour metastasis is highly improbable.  
RCC xenograft models show that resistance to sorafenib and most of the associated changes in gene expression 
are reversed by re-implantation of the resistant xenografts into untreated mice (100). This argues against any 
permanent genetic or epigenetic change in the tumour cells as an underlying mechanism and suggests that 
resistance, in part, relates to physiological changes in the microenvironment, enabling reestablishment of 
angiogenesis in the setting of VEGFR-blockade.  
Finally, re-exposure to targeted therapy after a period of discontinuation can be effective in a subset of mRCC-
patients. The efficacy of anti-VEGFR-TKI re-treatment was evaluated in 36 patients with disease progression after 
a TKI-everolimus sequence. The RR with TKI re-treatment was 8%, and the clinical benefit rate (PR plus SD) was 
75%. mPFS with each component of the TKI-everolimus-TKI sequence was 10.7, 8.9 and 8.2 months, 
respectively. mOS from the start of everolimus was 29.1 months, which suggests a benefit in using TKI in this 
setting. A potential bias may have been incorporated when selecting patients who went on to receive an 
additional anti-VEGFR-TKI after everolimus. The prolonged PFS observed with third-line (or higher) anti-VEGFR-
TKIs in this analysis suggests that mRCC may be re-sensitized to anti-VEGFR-TKI therapy after everolimus 
(101). Other reports have also suggested renewed anti-tumour activity of anti-VEGFR-TKIs after a period of 
treatment with an alternate mechanism of action or temporary discontinuation (102, 103).  
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5. PROGNOSTIC AND PREDICTIVE MARKERS IN CLEAR CELL RENAL CELL CARCINOMA TREATED 
WITH ANTI-VEGFR-TKIs 
 
Before summarizing all described prognostic and predictive markers associated with outcome in the metastatic 
setting under VEGF-blockade, we give here below an explanation on the differences between prognostic and 
predictive markers and an overview of prognostic markers after nephrectomy in localized RCC performed with 
curative intent. 
 
5.1. Prognostic and predictive markers 
 
When studying the outcome in anticancer therapies, it is important to distinguish between prognostic and 
predictive markers. Prognostic markers tell us something about the aggressiveness and spontaneous course of 
the disease: they are linked to the natural evolution of the disease. Predictive markers tell us something about the 
expected efficacy of a therapy, thus the potential impact of therapy on the further course of the disease. They 
predict if the disease will likely respond to the therapy or not.  
Common parameters measuring the evolution of the disease are PFS and OS: indolent tumours have a long PFS 
and OS, while aggressive tumours have a shorter PFS and OS. The efficacy of a therapy can be described by 
PFS, OS or the response rate (RR), which is the assessment of the frequency of tumour shrinkage on a given 
treatment. An efficient therapy should theoretically prolong PFS and OS, and can lead to clinically relevant tumour 
shrinkage.  
As PFS and OS are both affected by the biology of the disease and by therapeutic efficacy, it is not always easy 
to make a distinction between a predictive and a prognostic marker. An additional difficulty is that one marker can 
be predictive and prognostic at the same time, and even in the opposite direction. The best known example is 
HER2/neu-amplification in metastatic breast cancer: patients with HER2/neu positive breast cancer have a more 
aggressive disease, but they will specifically respond on HER2/neu-targeted therapy. Thus, HER2/neu-
amplification is a negative prognostic marker and on the same time a positive predictive marker.  
A prognostic marker can potentially influence both PFS and OS in the same way. A predictive marker could have 
an impact on PFS without any effect on OS, but can influence both, as a longer PFS can predict a longer OS. 
How to make thus the difference between a prognostic and a predictive marker?  
The easiest way to make the difference is to study the same marker on an untreated control group or on patients  
treated with placebo. If the effect of a marker on the outcome of an active therapy is not seen in the placebo-
treated group, then we have found a predictive marker. On the opposite, if the marker has the same impact in 
both treatment groups, independently of the given treatment, then we are dealing with a prognostic marker. 
Nevertheless, a placebo-controlled group is not always available. Only in two pivotal RCC studies with anti-
VEGFR-targeted therapies, with placebo control, research on predictive markers has been prospectively done: 
the pivotal trials of sorafenib and pazopanib (Table 3) (4, 21). 
Although less reliable, the RR could also give us some indications about the predictive value of a given marker. In 
fact, a reduction in size of the tumoral mass is rarely part of the natural evolution of the disease. Thus, if the 
reduction of the tumoral mass by a particular compound is influenced by a marker, this marker has a predictive 
value. Of note, the RR to RCC treatments in the pre-TKI era did not correlate with survival. 
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Moreover, markers clearly linked to pharmacokinetics, more in particular absorption, metabolism and excretion of 
therapeutic compounds, usually should play a predictive role, as they are not linked to tumour biology and 
malignancy. 
 
5.2. Prognosis of RCC after nephrectomy with curative intent for localized disease 
 
A multitude of prognostic factors predicting relapse after nephrectomy have been described. The anatomic extent 
of disease is the most consistent factor that influences prognosis. Five year survival rate is 90% in WHO stage I, 
75-95% in stage II and 59-70% in stage III tumours. In stage IV tumours, mOS is 16 to 20 months. Histologic 
grade is an independent factor correlating with survival: five-year survival rates of 89, 65, and 46% for tumours of 
histologic Fuhrman grade 1, 2, and 3-4, respectively, were reported (13, 104, 105). A poor prognosis is 
associated with the presence of a sarcomatoid pattern (106).   
Negative clinical prognostic signs include the presence of symptoms and/or para-neoplastic syndromes, obesity, 
a poor performance status, baseline serum lactate deshydrogenase (LDH) levels, baseline corrected calcium 
levels, baseline haemoglobin and the interval between the initial diagnosis and the start of systemic therapy. The 
latter five parameters, that are part of the MSKCC score, were analysed in a series of 118 patients who all had 
developed a recurrence following nephrectomy for localized disease. Patients with none of these risk factors 
constituted a low-risk group, while those with one or two risk factors had an intermediate risk and those with three 
or more were at high risk for shortened survival. mOS after nephrectomy for low-, intermediate-, and high-risk 
groups was 76, 25, and 6 months, respectively (107).  
Although none of these factors has an established role independent of stage, some molecular parameters have 
shown promise as prognostic markers in patients with ccRCC in the post-nephrectomy setting. Lack of B7H1 and 
B7H4 expression in patients have been strong predictors of OS (108, 109). Low levels of carbonic anhydrase IX 
(CAIX) expression and high levels of Ki67, detected by IHC, were associated with a significantly worse prognosis 
(107). Patients with a deletion of chromosome 9p have more aggressive disease at presentation, manifested by 
significantly larger tumours, higher Fuhrman grade, and an increased frequency of lymph node and distant 
metastasis. In patients with chromosome 9p deletion and small (<4 cm) solitary renal masses, there was an 
increased risk of disease recurrence (110). m-ccRCC patients with chromosome 8q amplifications (111) or 
chromosome 14q loss (112) had poor survival. In ccRCC, higher VEGF expression correlated with higher tumour 
size, higher Fuhrman grade, tumour necrosis, higher tumour stage, RCC progression rate and lower RCC-specific 
survival (113, 114). 
VHL-disease-associated ccRCCs seem to grow more slowly and are associated with an overall better prognosis 
than sporadic ccRCCs (115, 116). Sporadic ccRCCs that lack functional VHL-protein might, therefore, be 
expected to have a better prognosis than sporadic ccRCCs resulting from VHL-independent mechanisms of 
pathogenesis and tumorigenesis. However, although the results of some studies seem to support this hypothesis 
(32, 117), others have found no association between the presence or absence of VHL-alterations and prognosis 
or adverse clinical and pathological features (36, 115, 118-122). Results of a large case-control study in patients 
with RCC showed that the presence of VHL nonsense mutations was strongly associated with increased tumour 
grade and lymph-node involvement, and that such mutations were particularly prevalent in patients with 
metastatic disease (36). 
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Multiple models have been developed to integrate the information from anatomic staging with histopathology and 
clinical prognostic parameters. The most widely studied prognostic model has been the UCLA integrated staging 
system which incorporates the Eastern Cooperative Oncology Group Performance Status (ECOG PS) and 
Fuhrman's histologic grade (1 through 4) into the TNM anatomic staging system. Using these variables, five 
distinct prognostic categories were identified that correlate with post-nephrectomy outcome.  
Finally, expression-profile based subgroups of ccRCCs such as those described by Brannon et al. and the TCGA 
seem also to have a prognostic impact:  in both studies, there was an association between the molecular 
subgroups and post-nephrectomy survival (64, 66). For cancer-specific survival after nephrectomy, Brannon’s 
ccA-subtype was associated with a highly significant survival advantage over ccB-patients (p=0.0002, mOS of 8.6 
versus 2 years). At 5 years, cancer-specific survival was 56% in ccA-patients and only 29% in ccB-patients. The 
same impact was observed for OS, with a significantly greater survival for ccA-patients over ccB-patients 
(p=0.004, mOS of 4.9 versus 1.8 years). At 5 years, survival for ccA-patients was 48% but only 23% for ccB-
patients. 
 
5.3. Clinical-biological markers and prognostic scoring systems 
 
5.3.1. Routinely available clinical and biochemical markers 
 
Several routinely available clinical and biological markers linked to PFS and OS have been described and 
combined in prognostic scoring systems.  
Five factors predicting shortened survival were identified in a series of 670 patients with advanced RCC treated 
with immunotherapy at the MSKCC (table 4): A Karnofsky performance status (KPS) of <80, serum LDH-level 
>1.5 times the upper limit of normal, corrected serum calcium >10 mg/dL (2.5 mmol/L), haemoglobin 
concentration less than the lower limit of normal and absence of nephrectomy (no disease-free interval). Patients 
with none of these risk factors (good prognosis group) versus those with one or two (intermediate prognosis 
group) versus those with three or more risk factors (poor risk group) had significantly higher survival rates at one 
(71 versus 42 and 12%, respectively) and three years (31 versus 7 and 0%, respectively) (27). A follow-up 
analysis with 463 patients who were treated with IFN-alpha identified an interval of less than one year from initial 
diagnosis to the start of IFN-alpha therapy as an additional indicator of a poor prognosis (8). This parameter 
replaced the parameter ‘absence of nephrectomy’ in the score. In this report, the mOS for patients with good, 
intermediate or poor risk was 30, 14, and 5 months, respectively. 
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PROGNOSTIC FACTORS ONE POINT IF TOTAL SCORE  
Karnofsky PS < 80 0: favourable prognosis 
1-2: intermediate prognosis 
3-5: poor prognosis 
Interval between diagnosis and 
start of systemic treatment  
< 12 months 
(or no nephrectomy) 
Haemoglobin < lower limit of normal 
11.5 g/dl in women 
13.0 g/dl in men 
LDH > 1.5 upper limit of normal 
Corrected calcium > 10.00 mg/dl 
 Table 4: MSKCC prognostic factors for OS in mRCC (8) 
 
The MSKCC prognostic model was validated and extended in a series of 353 previously untreated patients with 
mRCC at the Cleveland Clinic (123). Two additional significant negative prognostic factors were identified: prior 
radiotherapy and the presence of more than one site of metastatic disease. Patients with favourable (no more 
than one poor prognostic factor), intermediate (two prognostic factors), or poor risk (more than two) disease had a 
mOS of 26, 14, and 7 months, respectively. 
In a series of 375 patients who received sunitinib in the registration trial, high corrected calcium levels, a high 
number of metastatic sites (more than one), the presence of liver metastases, baseline thrombocytosis, a shorter 
time from diagnosis to treatment (less than one year) and higher baseline serum LDH-levels were associated with 
a shorter PFS. Based on this results, a nomogram for predicting 12-months PFS was established (124).  
Patil et al. checked the different parameters of the MSKCC-score prognostic for OS and developed during the era 
of immunotherapy on the 375 patients included in the sunitinib pivotal trial. Multivariate analysis identified 5 
factors as significant predictors for PFS (serum LDH-level, presence of ≥2 metastatic sites, absence of prior 
nephrectomy, ECOG PS and baseline platelet count) and 6 independent factors for OS (serum LDH-level, 
corrected serum calcium level, time from diagnosis to treatment, haemoglobin level, ECOG PS and presence of 
bone metastasis). The authors concluded that the MSKCC model for OS is applicable in the era of targeted 
therapy but added a new independent factor for OS: the presence of bone metastases (125). 
The IMDC developed a scoring system based on 645 mRCC patients (clear cell and non-clear cell) treated with 
three anti-VEGF-targeted drugs including sunitinib (n=396), sorafenib (n=200) or bevacizumab (plus IFN-alpha) 
(n=49) as first-line anti-VEGF-targeted therapy. Four of the 5 MSKCC criteria for OS were confirmed as 
independent predictors of short survival (baseline haemoglobin, baseline corrected calcium, baseline KPS<80, 
interval between diagnosis and start of systemic treatment less than one year), and two new factors were added: 
baseline neutrophil count and platelet counts higher than the upper limit of normal. Based on these criteria, 
patients were divided into favourable risk (no adverse prognostic factors), intermediate risk (one or two adverse 
prognostic factors) or poor risk (three or more adverse prognostic factors) categories. mOS for good-risk patients 
had not been reached and was 27 and 9 months, respectively, for the intermediate and poor-risk groups (9). In 
2013, Heng et al. validated this score on an independent series of 1.028 patients (126).  
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PROGNOSTIC FACTORS ONE POINT IF TOTAL SCORE  
Karnofsky PS < 80 0: favourable 
prognosis 
1-2: intermediate 
prognosis 
3-6: poor prognosis 
Interval between diagnosis and start 
of systemic treatment  
< 12 months 
(or no nephrectomy) 
Haemoglobin < lower limit of reference 
11.5 g/dl in women 
13.0 g/dl in men 
Baseline neutrophil count  > 4.500/mm³ 
Corrected calcium > 10.00 mg/dl 
Baseline platelet counts > 400.000/mm³  
Table 5: IMDC prognostic score for OS in mRCC (9) 
 
Most of these clinical and biochemical markers are also valid in placebo-treated patients, they have a prognostic 
but not a predictive value (127). They are almost all the reflection of the clinical stage of the malignancy and of the 
impact of the disease on the general state of the patient.  
 
5.3.2. Tumour burden 
 
In a series of 124 m-ccRCC patients treated with sorafenib or sunitinib (66%) or placebo (34%), tumour burden 
was directly related to PFS and OS and these associations remained significant after adjusting for MSKCC risk 
class and treatment. Each 1-cm increase in tumour burden increased the risk of progression by 4.5% and the risk 
of death by 5%. When adjusting for age, gender, MSKCC risk group (high- versus low-/intermediate-risk group), 
active therapy (yes versus no) and type of study, the increase in tumour burden remained associated with a 
higher risk of progression. In multivariable analysis adjusted for MSKCC prognostic score groups, the tumour 
burden remained an independent prognostic factor for death. The mOS value for tumour burden above the 
median was 16.4 months compared with 27.4 months for patients with tumour burden below the median; the 
differences were maintained when adjusted for treatment (128). In another study on 69 m-ccRCCs treated with 
sunitinib, tumour burden was found to be a significant predictor of PFS and OS (129). 
Other arguments in favour of the impact of tumour burden come from the impact of nephrectomy on outcome. In 
the era of immunotherapy, nephrectomy, even in locally advanced and metastatic setting, was proved to be a 
factor of good prognosis (27). A reduction of the tumour load could decrease immunosuppressive effects of the 
tumour and decrease the amount of tumour stimulating cytokines released by the tumour.  
 
5.3.3. Side effects under anti-VEGFR-TKIs associated with efficacy 
 
The incidence of TKI-induced side effects like hand-foot-syndrome, hypothyroidism and hypertension were in 
some studies associated with efficacy. This association can be explained by the parallelism between toxicity and 
efficacy in function of the plasma levels of the active compounds, but biases are easily possible. The longer a 
patient stays on treatment, the higher the probability that he will develop side effects. Thus, the incidence of this 
specific side effects should always be related to duration of therapy. The most solid data are on the association 
between the development of hypertension with anti-VEGFR-TKIs and outcome. In a series of 111 mRCC patients 
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treated with sunitinib, the development of hypertension during sunitinib treatment was a positive predictive factor 
associated with a significantly longer PFS and OS. A disadvantage of this approach is that these adverse events 
only appear once the treatment is started. Thus, they cannot predict efficacy of a planned treatment (130). 
 
5.3.4. Site of metastasis 
 
As anti-VEGFR-targeted therapy is also acting on the tumour microenvironment, efficacy could be very different 
depending on the site of metastasis. In the MSKCC nomogram predicting PFS, the presence of liver metastases 
was associated with a shorter PFS (124). Pancreatic metastases seem to be associated with a better OS (131).  
 
5.4. Histology 
 
The presence of sarcomatoid dedifferentiation in the primary tumour has a negative impact on outcome on anti-
VEGFR-TKIs in the metastatic setting. In a series of 43 sarcomatoid mRCC treated with anti-VEGF-targeted 
therapy, PR was observed in 19%, stable disease (SD) in 49% and early progressive disease (PD) in 33% of 
patients. mPFS and OS were 5.3 and 11.8 months, respectively. PRs were confined to patients with tumours with 
<20% of sarcomatoid elements. Early PD was observed in only 22% of these patients, while early PD presented 
in 56% of the patients who had >20% of sarcomatoid elements in their primary tumours. The differences in PFS 
(6.8 versus 4.3 months) and OS (14.9 versus 8.6 months) favoured the group that had <20% of sarcomatoid 
elements, but these differences were not statistically significant (132).  
The second largest series of mRCC patients with sarcomatoid dedifferentiation treated with anti-VEGF-targeted 
therapy involved 32 patients treated with first-line sunitinib (29 patients) or sorafenib (3 patients). Of the patients 
treated with sunitinib, 14% had a PR, 59% had SD and 28% PD as best response. Five patients received sunitinib 
as second-line therapy and one of these patients achieved a CR. mPFS and mOS under sunitinib were 4.4 and 
10 months, respectively (133). Unfortunately, Golshayan and Molina did not have a control group of patients 
without sarcomatoid dedifferentiation. 
 
5.5. Non-routine serum markers 
 
5.5.1. Baseline VEGF-levels 
 
Unless the important role of VEGF in early neo-angiogenesis, it has been difficult to determine the prognostic and 
predictive role of serum VEGF-levels. Contradicting results may be due to problems of VEGF-detection. Elevated 
baseline serum VEGF-levels seem to be a negative prognostic marker in RCC. In mRCC patients treated with 
immunotherapy, higher baseline serum VEGF-levels predicted poorer PFS and OS (134). However, in other 
studies, this association was not confirmed (135, 136). In patients treated with sorafenib or placebo in the pivotal 
phase III trial, higher baseline VEGF-levels were associated with poorer OS in both treatment arms (2, 85). 
Increased baseline VEGF-level was also found to be associated with decreased survival in sunitinib treated 
patients. Patients with higher baseline VEGF-levels had a higher probability of disease progression (137).  
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On top of a negative prognostic value, higher VEGF-levels might have an additional positive predictive value. In 
the pazopanib pivotal trial, when comparing OS in patients treated with placebo and pazopanib and with low and 
high baseline VEGF-levels, higher VEGF-levels were a negative prognostic markers for OS in both treatment 
groups, but associated with a larger relative OS benefit when treated with pazopanib (127). In the placebo group 
of the sorafenib pivotal trial, high baseline VEGF patients had a shorter PFS than patients with low baseline 
VEGF, reflecting an aggressive tumour and thus indicating that high baseline VEGF-levels have a negative 
prognostic value. Nevertheless, patients with high baseline VEGF-levels derived more benefit from sorafenib 
relative to placebo than those who had low baseline VEGF-levels, although the mPFS for sorafenib treatment in 
both groups was the same (2).  
 
5.5.2. Evolution of VEGF, sVEGFR2 and sVEGFR3 during therapy 
 
In a biomarker analysis from the sunitinib phase II trial in cytokine-refractory RCC patients, significantly larger 
changes in VEGF- (increased during treatment) and soluble VEGFR2- and VEGFR3-levels (both decreased 
during treatment) were seen in patients who yielded a PR to treatment than in those who had SD or PD (86, 138). 
For pazopanib, a decrease in serum VEGFR2-levels during therapy was also linked to improved response and 
PFS (139). In the sorafenib registration trial, serum VEGFR2-levels declined under treatment with sorafenib, but 
not in the group treated with placebo. Nevertheless, the authors did not study the link between the decrease of 
the biomarker and treatment outcome (85).  
 
5.5.3. Baseline serum levels of IL-6 and IL-8 
 
IL6 is a potent inducer of an inflammatory reaction and IL8 an alternative VEGF-independent pro-angiogenic 
factor. In a series of 225 pazopanib treated mRCC patients, higher baseline serum IL6- or IL8-levels were 
associated with a more pronounced tumour shrinkage (IL8), shorter PFS (IL6 and IL8) and OS (IL6). These 
associations were also found in 118 placebo-treated patients, indicating the prognostic value of these cytokines. 
Nevertheless, higher baseline IL6- or IL8-levels were associated with a larger relative benefit when treated with 
pazopanib, suggesting that on top of a negative prognostic value, higher baseline IL6- or IL8-levels might also 
have a positive predictive value (127).  
 
5.6. Molecular markers 
 
 
5.6.1. VHL-mutation and hyper-methylation 
 
Given the important role of the loss of VHL-function in the molecular pathogenesis of RCC and in VEGF-
dependent angiogenesis, an attractive hypothesis was that VHL-mutation or VHL-hyper-methylation would render 
a tumour more VEGF-dependent and that VHL-wild type tumours would be rather resistant to anti-angiogenics. 
Nevertheless, this hypothesis could never be confirmed. In a series of 43 m-ccRCC patients, 26 (60%) had VHL-
mutations or promoter hyper-methylation and 17 (40%) were VHL-wild type. The RR on anti-angiogenic drugs 
(bevacizumab plus IFN-alpha, sunitinib or axitinib) was 48% versus 35% with a mTTP of 10.8 versus 5.5 months 
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(p=0.26), respectively. In 15 patients with VHL-methylation or VHL-mutation predicted to truncate or shift the VHL 
reading frame, mTTP was 13.3 versus 7.4 months (p=0.06) in patients with none of these features (140).  
In a series of 123 m-ccRCC patients treated with sunitinib (51%), sorafenib (23%), axitinib (12%) or bevacizumab 
(14%), the overall frequency of VHL-mutations was 49%, and 78% of these mutations were predicted to result in 
the loss of function of the VHL-protein (frame shift, nonsense, splice site, and in-frame deletions or insertions). 
Ten percent of patients had VHL-promoter hyper-methylation. The RR was not significantly different in patients 
with inactivated (mutated or methylated) VHL compared with those who had wild-type VHL (41% versus 31%, 
p=0.34). Patients with loss of function mutations had a 51% RR, compared with 31% in wild-type VHL-carriers (p-
value: 0.04). On multivariate analysis, that included several other important clinical prognostic factors, the 
presence of a loss of function mutation remained an independent prognostic factor associated with improved 
response. Nevertheless, PFS was not modified: patients with VHL-mutation had a mPFS of 12 months versus 9 
months for VHL-wild-type patients and 11 months for VHL hyper-methylated patients (p=0.78). Patients with a 
VHL-loss-of-function-mutation had a mPFS of 13.7 months versus 9 months for VHL-wild-type patients (p=0.71) 
(141).  
This surprising finding can probably been explained by the fact that other mechanisms beside VHL-mutations or 
promoter hyper-methylation can lead to the dysfunction of VHL-protein or HIF-stabilization. In ccRCCs without 
VHL-mutation or promoter hyper-methylation, other mechanisms of VHL-impairment or HIF-stabilization are often 
present. This could explain why it has been difficult to find associations between outcome on anti-VEGFR-TKIs 
and mutations or promoter-hyper methylation of VHL. 
 
5.6.2. Germ-line polymorphisms 
 
Recently, three studies have described associations between single nucleotide polymorphisms (SNPs) in genes 
involved in sunitinib or pazopanib pharmacokinetics (ABCB1, NR1/2 and NR1/3), sunitinib or pazopanib 
pharmacodynamics (PDGFR-alpha, VEGFR2 and VEGFR3) and VEGF-independent pro-angiogenic pathways 
(FGFR2, IL8) and treatment outcome on these anti-VEGFR-TKIs in patients with mRCC. These studies are 
described in detail in Part 3, 4 and 5 of the Results section (142-144).  
 
5.6.3. Expression levels of hypoxia markers 
 
In a series of 67 m-ccRCC patients treated with sunitinib, the expression of proteins involved in hypoxia pathways 
was analysed by IHC. Associations were observed between high expression of HIF2-alpha and PDGFR-beta and 
better sunitinib RECIST objective response. Increased VEGFR3-expression was associated with longer PFS. 
VEGFR3-overexpression showed a negative correlation with VEGFR3 polymorphism rs307826, a sunitinib 
resistance predictor. High VEGF-A was associated with short OS and HIF2-alpha with long OS (145). 
In a second series of 42 m-ccRCC patients treated with sunitinib, higher HIF1-alpha, VEGFR3 and CD34 (as an 
assessment for microvessel density) staining were associated with better PFS. Higher VEGFR1 and VEGFR3 
staining were associated with better OS. Tumours with characteristics of good prognosis such as low Fuhrman 
grade and low T-stage (T1 or T2), absence of lymph nodes and absence of synchronic metastases displayed 
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higher mean expression of CD31, CD34, HIF1-alpha, VEGFR1, -2 and -3 vessel staining as well as PDGFR-
alpha and –beta score and intensity (146).  
In a third series of 40 m-ccRCC patients, high VEGFR2-levels, as assessed by IHC on the primary nephrectomy 
specimen, were associated with improved PFS on multivariate analysis when treated with sunitinib (147).  
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OBJECTIVES OF THE RESEARCH 
 
The objective of this PhD project was to investigate new clinical, biochemical, pathological and molecular markers 
predictive for response in m-ccRCC patients treated with anti-VEGFR-TKIs. Additionally, we aimed to describe 
further prognostic markers in m-ccRCCs treated with these therapies. 
The specific materials and methods of each subunit of our work are described in the corresponding chapters. For 
the entire project, we used a newly established clinical database, a tissue collection of paraffin embedded tumour 
slides, a frozen tumour bank and germ-line DNA samples.  
Between 2009 and 2013, the clinical database of patients with mRCC treated with anti-VEGF-targeted therapy 
included 531 cases, originating from the following centres: University Hospitals Leuven (Leuven, Belgium): 230 
patients, Algemeen Ziekenhuis Groeninge (Kortrijk, Belgium): 35 patients, Hôpital Européen Georges Pompidou 
(Paris, France): 97 patients, Institut Gustave Roussy (Villejuif, France): 67 patients, Centre Hospitalier 
Universitaire Strasbourg (Strasbourg, France): 17 patients and other institutions in France: 85 patients. Among 
these cases, 408 were m-ccRCC patients treated in first-line anti-VEGF-targeted therapy with sunitinib. Moreover, 
the database also contained 55 files of m-ccRCC patients treated in first-line with pazopanib or sorafenib. 
Furthermore, a fully annotated RCC tumour bank based at INSERM U674 “Génomique fonctionelle des tumeurs 
solides”, linked to Université Paris-5 René Descartes, headed by Prof. Dr. Zucman-Rossi, was established. This 
tumour bank contains 288 fresh frozen samples, including 132 ccRCCs treated first-line in the metastatic setting 
with sunitinib with complete follow-up of the clinical data. Samples were collected in France (96 samples) and at 
University Hospitals Leuven (36 samples). Data on response to sunitinib are available. The tumour bank also 
contains corresponding normal kidney tissue from these patients. For germ-line DNA investigations, we used the 
frozen normal kidney tissue as well as peripheral blood of those patients in whom frozen non-tumoral tissue was 
not available.  
Most of the patients included in this research work were treated in first-line with sunitinib, fewer patients with 
pazopanib or sorafenib. As the therapeutic efficacy of anti-VEGFR-TKIs was an important endpoint of our  study, 
only RCCs with clear cell histology were included. In study parts where the efficacy of bone targeted therapies or 
toxicity of the VEGFR-TKIs and pharmacokinetic aspects of sunitinib were studied, some patients with non-
ccRCC were included. Unfortunately, no samples or clinical data from placebo treated patients were available for 
our project. 
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ABSTRACT  
Background: There is growing evidence that sunitinib plasma levels have an impact on treatment  outcome in 
patients with metastatic renal cell carcinoma (mRCC). We studied the impact of single nucleotide polymorphisms 
(SNPs) in genes involved in sunitinib pharmacokinetics, and additionally, sunitinib pharmacodynamics on dose 
reductions of the tyrosine kinase inhibitor. 
Methods: We retrospectively analysed normal DNA retrieved from mRCC patients receiving sunitinib as first-line 
therapy. We genotyped 11 key SNPs, respectively in ABCB1, NR1/2, NR1/3 and CYP3A5, involved in sunitinib 
pharmacokinetics as well as VEGFR1 and VEGFR3, which have been suggested as regulators of sunitinib 
pharmacodynamics. Association between these SNPs and time-to-dose-reduction (TTDR) was studied by Cox 
regression. 
Results: We identified 96 patients who were treated with sunitinib and from whom germ-line DNA and data on 
dose reductions were available. We observed an increased TTDR in patients carrying the TT-genotype in ABCB1 
rs1125803 compared to patients with CC- or CT-genotypes (19 versus 7 cycles; p=0.031 on univariate analysis 
and p=0.012 on multivariate analysis) and an increased TTDR in patients carrying the TT/TA-variant in ABCB1 
rs2032582 compared to patients with the GG- or GT/GA-variant (19 versus 7 cycles; p=0.046 on univariate 
analysis and p=0.024 on multivariate analysis).  
Conclusion: mRCC patients carrying the rs1128503 TT-variant or the TT/TA-variant in rs2032582 in ABCB1, 
which encodes for an efflux pump, do require less dose reductions due to adverse events compared to patients 
with the wild type or heterozygote variants in these genes.  
 
KEYWORDS: renal cell carcinoma, sunitinib, ABCB1 efflux pump, single nucleotide polymorphisms, dose 
reductions 
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INTRODUCTION  
Inactivation of the von Hippel–Lindau (VHL) tumour suppressor gene is the most frequent molecular alteration in 
clear cell RCC. Inactivated VHL leads to elevated protein levels of hypoxia-induced factor-α which upregulates the 
vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF) pro-angiogenic signaling 
pathways. Targeted therapies directed against the VEGF- and PDGF-receptor have significantly improved the 
outcome of patients with mRCC. Sunitinib malate is an orally administered tyrosine kinase receptor inhibitor (TKI) 
that targets VEGF and PDGF receptors, KIT, FLT-3, colony stimulating factor-1 receptor, and RET. In a 
randomized controlled trial sunitinib significantly prolonged progression-free-survival (PFS) (11 versus 5 months, 
p<0.001) as compared to interferon alpha [1]. Median overall survival (OS) was 26.4 and 21.8 months, 
respectively (p=0.051) [2]. Sunitinib is a current standard treatment option in mRCC, but other anti-VEGFR and 
anti-PDGFR-targeted TKIs like sorafenib, pazopanib and axitinib are also used in certain clinical settings. 
Although 50% of RCC patients receiving sunitinib experience an objective response and 43% achieve disease 
stabilization, 7% will experience progressive disease (PD) at first evaluation probably due to intrinsic resistance or 
due to other factors [2]. Moreover, even patients with an initial clinical benefit will finally progress due to acquired 
resistance or for other reasons. Although different mechanisms of primary and secondary resistance have been 
proposed, reliable biomarkers predictive of sunitinib sensitivity or primary/secondary resistance are still lacking 
[3].  
Sunitinib plasma levels are not dosed in clinical routine, even though it is known that sunitinib plasma levels might 
impact efficacy of sunitinib treatment in mRCC. A population pharmacokinetic analysis of sunitinib and its primary 
active metabolite, SU12662, found that the pharmacokinetics of both compounds were significantly influenced by 
several covariates including gender, age, and weight; however, the magnitude of the predicted changes in 
exposure minimized the necessity for dose adjustments [4]. A meta-analysis of pharmacokinetic data from 443 
patients treated with sunitinib showed that higher plasma levels of sunitinib and its active metabolite SU12662 
were associated with prolonged time-to-tumour-progression (TTP) and OS [5]. Other studies have shown that the 
occurrence of adverse events, in particular hypertension, is possibly linked to improved treatment outcome [6]. 
Finally, several studies in RCC have shown associations between polymorphisms in genes linked to sunitinib 
pharmacokinetics and outcome on sunitinib [7-10] or pazopanib [11-12].  
The main objective of the present study was to analyse the impact of SNPs in selected genes potentially linked to 
sunitinib pharmacokinetics (ABCB1, NR1/2, NR1/3 and CYP3A5) and the occurrence of dose reductions during 
treatment. Additionally, we analysed the impact of SNPs in two genes encoding sunitinib targets (VEGFR1 and 
VEGFR3), linked to sunitinib efficacy, and the occurrence of dose reductions.   
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MATERIALS AND METHODS 
 
For the purpose of this retrospective study, germ-line DNA samples were collected from the “CIT-rein” kidney 
tumor bank and from patients treated at the University Hospitals Leuven. The French-Belgian multicentric “CIT-
rein” kidney tumor bank contains more than 250 frozen pathologically confirmed RCC tumor samples collected at 
20 academic hospitals. In the “CIT-rein” kidney tumor bank, we selected the samples of patients treated in first-
line with sunitinib at a starting dose of 50 mg/day 4 weeks on, 2 weeks off and of whom frozen normal kidney 
tissue as well as data on dose reductions were available. In order to extend the series, we sampled peripheral 
blood in all the RCC patients treated at the University Hospitals Leuven from July 2011 till December 2012 
applying the inclusion criteria. Eligible patients could have received cytokines as systemic treatment for kidney 
tumors, but they could not have received any other TKI or mammalian target of rapamycin (mTOR) inhibitor 
before starting sunitinib.  
Dose reduction policy and timing of clinical radiological assessments were left to the discretion of the attending 
doctors in accordance with current local practice guidelines. Usually, whenever necessary for tolerance issues, in 
a first step, the dose is reduced to 37.5 mg/day and, if necessary, in a second step to 25 mg/day. In some 
patients, sunitinib is definitively stopped for tolerance issues.  
The endpoint of this study was time-to-dose-reduction (TTDR), calculated as the time between the start of 
sunitinib and the occurrence of a dose reduction to 37.5 mg/day or of definitive stop of sunitinib for tolerance 
issues. Therefore, in this study, the SNPs were primarily evaluated as toxicity-related markers, although it was 
also foreseen to check our previous findings on associations between these SNPs and outcome in this patient 
series in order to show the inverse correlation between TTDR and outcome. If a patient’s regimen was switched 
from 50 mg/day to 37.5 mg/day continuously because of flare-up during the two weeks off sunitinib, this was not 
considered as a dose reduction for adverse event and the censing was closed at the moment of dose adaptation.  
For the statistical analysis, the genotypes were combined as much as possible, as it was done in the original 
publications. Details and exceptions to this rule are documented in the legend of table 4.  
For those SNPs that were significantly associated with TTDR, we also analyzed their association with PFS and 
OS. For this efficacy analysis, only patients with clear cell RCC were considered as previous publications on 
associations between polymorphisms and efficacy were only reported in clear cell RCCs. Moreover, for the 
efficacy analysis, all the patients had to complete at least one cycle of sunitinib and had to reach at least the first 
evaluation by CT scan. Response evaluation was done by RECIST in most of the cases. 
The protocol was approved by the medical ethics review boards of all participating institutions, and signed 
consent was obtained from all patients. In some cases, we used frozen biologic material from patients who had 
already died and for whom a general positive advice for the utilization of remaining tissue was foreseen by the 
institutional board.  
SNPs with potential relevance for sunitinib dose reductions were selected from the literature (Table 1A and 1B). In 
particular, we included SNPs in genes linked to sunitinib or pazopanib pharmacokinetics or pharmacodynamics 
associated with efficacy and/or dose reductions in previous publications with sunitinib [6][7][8][9] or pazopanib 
[10][11].   
DNA was isolated from fresh frozen normal kidney tissue sampled in the nephrectomy specimen using the 
Qiaquick extraction kit (Qiagen, Valencia, CA, USA) and quantified by fluorometry (Fluoroskan Thermo 
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Labsystems, Cergy-Pontoise, France). DNA was isolated from peripheral blood with the Qiagen DNA kit (Qiagen, 
Valencia, CA, USA) and the final DNA concentration was quantified with Nanodrop (Nanodrop, Wilmington, USA). 
High-throughput SNP genotyping was performed using the Sequenom MassArray platform [12]. Investigators 
blinded for the clinical data performed the genotyping analysis. Overall, the 11 selected SNPs were successfully 
genotyped with success rates ≥92% for each SNP and an overall average success rate of 98%. For most of the 
SNPs, genotypes were analyzed in the same way as they were described in the original reports (i.e., according to 
dominant, recessive or co-dominant genetic models or in the context of a specific haplotype). Details are given in 
table 4. 
Clinical data were collected at 12 different sites in France (11) and Belgium (1). TTDR, PFS and OS were 
calculated by Cox regression. Based on the data of Houk et al [4], we considered that gender, age and general 
shape of the patient as reflected by his IMDC prognostic score could influence tolerance and as a consequence 
TTDR. These factors were tested in univariate analysis, except patient weight which was not available. Any 
parameter related to TTDR in univariate analysis by Kaplan-Meier with a p-value <0.2 was included in the 
multivariate model (Cox regression). Without correction for multiple testing, results with a p-value of <0.05 were 
considered as significant.  However, correction for multiple testing by Bonferroni, taking into account the fact that 
the correlation with 11 SNPs was analyzed, indicated a p-value of <0.005 as the threshold for significance. 
Statistical analyses were conducted using GraphPad Prism 5 (GraphPad Software, La Jolla, UCLA) and XLSTAT 
software (Addinsoft, Paris, France).  
 
RESULTS 
 
We used tissue and clinical information from 96 patients who started sunitinib between November 2005 and 
November 2012 and closed the follow-up database in June 2013. For 72 patients, frozen normal kidney samples 
from the “CIT-rein” kidney tumor bank were used and for 24 additional patients treated in Leuven, peripheral 
blood was used. The data of 81 of these patients were used in a previous publication on the impact of ABCB1 
polymorphisms on outcome by our own group [8]. Table 2 shows the clinical characteristics of these patients. 
Mean age at diagnosis was 59 years (range 25-84). The majority of patients (>95%) were of Caucasian origin. 
According to the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) prognostic criteria 
[13], 14% of patients were categorized into the favorable risk group, 59% had intermediate and 27% poor risk.  
Fourty-nine out of 96 patients (51%) required dose reductions or definitive stop of sunitinib after a median TTDR 
of 5 cycles (46 dose reduction and 3 treatment withdrawal). Median TTDR in all patients, i.e., in those undergoing 
dose reduction and those not undergoing dose reduction, was 9 cycles. The most frequent reason for dose 
reduction were hand foot skin reactions (17 patients), followed by diarrhea (14 patients), fatigue (9 patients), 
arterial hypertension (5 patients) and thrombocytopenia (5 patients). Less common reasons for dose reductions 
were anorexia, cardiotoxicity, mucositis, nausea and neutropenia. At the time of analysis, 71 (74%) patients had 
progressed and 59 (61%) had died. The median follow-up was 59 months (range 2 – 89 months) after the start of 
sunitinib. The median PFS of the whole study population  was 15 months and the median OS 29 months. Best 
response could be evaluated in 91 patients. Seven of 91 (7.7%) patients had a complete response (CR), 33/91 
(36.3%) patients a partial response (PR), 37/91 (40.7%) stable disease (SD) and 14/91 (15.4%) progressive 
disease (PD) as best response.  
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For each of the 11 genotyped polymorphisms the respective genotypes, allele frequencies and changes at the 
amino acid level are described in Table 3. The observed allele frequencies for each polymorphism were similar as 
previously reported in the dbSNP database (dbSNP build 136) or 1000 Genomes Project, except for SNPs 
rs2276707. 
The association between these polymorphisms and TTDR, as assessed by univariate analysis, are reported in 
Table 4 and displayed in Figures 1-3. We observed increased TTDR in patients carrying the rs1125803 TT-
genotype compared to patients carrying the CC- or CT-genotypes in ABCB1 (19 versus 7 cycles; p=0.031). 
Likewise, we observed increased TTDR in patients carrying the TT/TA-variant in ABCB1 rs2032582 (19 versus 7 
cycles; p=0.046), but rs1128503 and rs2032582 were in high linkage disequilibrium (r²=0.984) with each other. 
We also observed increased TTDR in patients with the TT-genotype in NR1/2 rs2776707 compared to patients 
with CC- and CT-genotypes (41.5 versus 7 cycles; p=0.027). We could not observe any association between 
SNPs in NR1/3, CYP3A5, VEGFR1 and VEGFR3 and TTDR.  
In view of an adjusted p-value and of the multivariate analysis, we checked TTDR in female and male (10 versus 
9 months; p=0.13) and in IMDC good and intermediate versus poor risk patients (11 versus 7 months; p=0.054).  
Age at start of sunitinib (under or above the median age of 61 years) had no influence on TTDR (HR 0.89 (95%CI 
0.49-1.60); p=0.69). Unfortunately, patient weight at start of sunitinib therapy was not available in a considerable 
part of the patients. Taking in to account gender and IMDC, the adjusted p-value is 0.014 for rs1128503 in 
ABCB1, 0.025 for rs2032582 in ABCB1 and 0.063 for rs2776707 in NR1/2.  
In a next step, we introduced the other polymorphism in the multivariate analysis. Including gender, IMDC (good 
and intermediate versus poor), rs1128503 in ABCB1 and rs2776707 in NR1/2, the p-value for the association 
between these SNPs and TTDR were 0.012 and 0.058, respectively. With rs2032582 (in ABCB1 instead of 
rs1128503) and rs2776707, the p-value for the association between these SNPs and TTDR were 0.024 and 
0.060, respectively. Note that rs1128503 and rs2032582 were not included in the same multivariate analysis, 
because of their high linkage disequilibrium (r²=0.984). 
In a previous publication, we showed the impact of SNP rs1128503 in ABCB1 on outcome in mRCC treated with 
sunitinib. In order to show the inverse correlation between TTDR and outcome, we checked the impact of the 
SNPs associated with dose reductions on outcome. As there is no complete overlap with the previously published 
series, we report the outcome data of the present patient series. In patients with clear cell histology, we have 
found a trend to a shorter PFS (11.5 versus 16 months, p=0.078) and a shorter OS (24 versus 34 months, 
p=0.016) in patients with the TT-genotype compared to patients with the CC- and CT-genotypes in rs1125803 in 
ABCB1, a trend to a shorter PFS (15 versus 18 months, p=0.094) and a shorter OS (26 versus 41 months, p= 
0.012) in patients with the TT/TA-genotype compared to patients with the GG- and GA/GT-genotype in rs2032582 
in ABCB1 and a shorter PFS (7 versus 18 months; p=0.011) and a trend to a shorter OS (12 versus 31 months; 
p=0.14) in patients with the TT-genotype compared to patients with the CC- and CT-genotypes in rs2776707 in 
NR1/2 (Figures 4-5).  
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DISCUSSION 
 
The main objective of the present study was to analyze the impact of SNPs in selected genes potentially linked to 
sunitinib pharmacokinetics (ABCB1, NR1/2, NR1/3 and CYP3A5) and the occurrence of dose reductions during 
treatment. We hypothesized that patients carrying genotypes that reduce absorption of sunitinib or increase 
metabolism of sunitinib - through lower sunitinib plasma levels and less frequent adverse events - less frequently 
require dose reductions. 
In a series of 96 mRCC patients treated with sunitinib as first-line targeted therapy, we observed an association 
between SNP rs1128503 in ABCB1, rs2032582 in ABCB1 as well as SNP rs2776707 in NR1/2 and the time point 
of dose reductions during sunitinib treatment, although the latter was not confirmed on multivariate analysis. Our 
time-to-event approach enabled us to avoid lead-time bias, which could easily have occurred if we would have 
merely compared the incidence of dose reductions in subgroups with significantly different treatment durations. 
The impact of these SNPs on PFS and OS was also analyzed on these patients series, showing an inverse 
correlation between efficacy and dose-reductions. Note that in a previous publication, we had already reported on 
the association between these SNPs and outcome on a patient series including 81 patients of the present study. 
In lack of a placebo-treated control group, we cannot define if these SNPs have a prognostic or a predictive value 
for outcome, although the fact that these genes are involved in sunitinib pharmacokinetics points toward a 
predictive value. 
At the start of therapy, anti-VEGFR-TKIs are generally administered at a fixed dose irrespective of the age, 
gender, weight or length of the patient. In the case of sunitinib, the starting dose is 50 mg/day for 4 weeks, 
followed by two weeks off-treatment. Many patients require dose modifications, for instance dose reductions to 
37.5 mg/day or even 25 mg/day due to tolerance issues. In the pivotal sunitinib trial, 38% of patients had dose 
interruptions and 32% had dose adaptations due to toxicity [1]. Remarkably, Houk et al. observed that when 
doses are lowered to 37.5 mg/day or subsequently even to 25 mg/day due to tolerance issues, or even when the 
dose of sunitinib is increased to 62.5 mg/day of sunitinib in patients with good tolerance but in need for an 
increased anti-tumor activity, the plasma levels of sunitinib are remarkably similar in all patients irrespective of 
dose adaptation [5]. These data suggest that individual patient characteristics that influence TKI absorption, 
excretion and metabolism may indeed influence TKI plasma levels and as a consequence determine the time and 
frequency of a dose reduction.  
The efflux transporter ABCB1 (ATP binding cassette member B1, formerly known as P-glycoprotein or MDR1) is 
expressed in the intestine and liver and involved in the oral absorption and biliary secretion of several anticancer 
drugs [14]. This transporter may contribute to multidrug resistance in tumors by actively extruding drugs from 
cancer cells, particularly in RCC [15][16]. As a consequence, expression levels and functionality of these drug 
transporters, for instance due to polymorphisms, may have important consequences for the efficacy of sunitinib. 
The most common functional SNPs in ABCB1 are the synonymous 3435C>T (rs1045642) and 1236C>T 
(rs1128503) changes and the non-synonymous 2677G>T change (missense A893S/T rs2032582). Functional 
studies have shown that the haplotype of these three SNPs (rs1046542 – rs1128503 - rs2032582) alters the 
function of the efflux transporter including its substrate specificity. There are four publications showing an 
association between rs1128503 in ABCB1 and treatment outcome on anti-VEGFR-TKIs in mRCC (Table 1) 
favoring patients with CT- and CC-variants [6][7][8][11]. As a consequence, the TT-genotype could lead to a more 
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active efflux pump or more affinity of the pump for sunitinib, leading to lower sunitinib plasma levels. Our data 
suggesting an association between the TT-genotype and a delay in dose reductions supports this hypothesis.  
Although Garcia-Donas, on a series of 89 mRCC patients treated with sunitinib, did not observe a higher risk for 
dose reductions in patients with the ABCB1 rs1128503 TT-variant or the rs2032582 TT/TA-variant, he observed 
less hypertension in patients with these variants: HR for the development hypertension was 0.41 (95%CI 0.20-
0.81; p=0.011) for the rs1128503 TT-variant and 0.42 (95%CI 0.21-0.84; p=0.014) for the rs2032582 TT/TA-
variant [7]. Moreover, on a series of 115 mRCC patients treated with sunitinib, rs2032582 in ABCB1 was linked to 
sunitinib plasma concentrations (p<0.05) [17]. 
After absorption, sunitinib is converted to an equipotent metabolite, SU12662 [18]. Both sunitinib and SU12662 
are metabolized predominately by cytochrome (CYP) 3A4, and elimination is primarily via the feces. The 
expression of cytochrome CYP3A4, thought to be the key enzyme for the hepatic biotransformation of sunitinib, is 
regulated by the ligand-activated nuclear receptors NR1I2 (pregnane X receptor) and NR1I3 (constitutive 
androstane receptor) [19][20]. There is evidence that polymorphisms in NR1/2 and NR1/3 might be associated 
with outcome in mRCC treated with anti-VEGFR-TKIs (Table 1). Patients with the TT-genotype in rs2276707 in 
NR1/2, leading to a higher expression of CYP3A4, seem to have a shorter PFS and OS. Our findings of an 
association between the TT-genotype and a decreased delay in dose reductions supports this hypothesis. 
We could not find any association between the TT-variant in rs4073054 in NR1/3 and TTDR despite the fact that 
patients with this variant tend to have a worse outcome. Neither could we find any association between SNP 
rs776746 in CYP3A5 and TTDR, although it was shown that the AA- and AG-genotypes were link to improved 
treatment outcome [6] and to increased need for dose reductions [7].  
These findings, when validated, could have interesting clinical applications. In fact, a patient whose disease is 
primarily or secondarily resistant to sunitinib 50 mg/day, who has few side effects and who has the ABCB1 
rs1128503 TT-variant, the rs2032582 TT-variant or the NR1/2 rs2776707 TT-variant, could be a good candidate 
for a trial with sunitinib dose escalation to 62.5 mg/day or even 75 mg/day. There is evidence for the positive 
impact of dose escalation of some anti-VEGFR-TKIs on treatment outcome in mRCC. In a randomized phase II 
trial with sorafenib, dose escalation of sorafenib from 2x400mg/d to 2x600mg/d was foreseen. Forty three (66%) 
of 65 patients who progressed on sorafenib 2x400mg/d had their dose escalated and 42% of these patients 
achieved a reduction in tumour size and disease stabilisation. The median PFS was 3.6 months for patients 
escalated to sorafenib 2x600mg/d. The PFS of escalation of sorafenib was more effective than placebo in this 
setting [21]. 
Our study has several potential limitations. (A) It was a retrospective analysis of patients treated in several 
centers without a central protocol dictating schedule and dose modifications or timing and method of radiological 
assessments. (B) The clinical sites did not report precise data on different side effects with National Cancer 
Institute Common Toxicity Criteria scoring, only the date of dose reduction and the reason for it were reported. 
Nevertheless, we assume that in most cases, the dose was reduced for grade 3 toxicity. (C)  Sunitinib plasma 
level were not available. (D) Correction for multiple testing by Bonferroni, taking into account that the correlation 
with 11 SNPs was analyzed, indicated a p-value of <0.005 as the threshold for significance. Our results did not 
reach this level of significance, probably due to the small number of patients in our series. (E) Finally, there was 
better treatment outcome in our series (PFS 15.0 and OS 29.0 months) compared to the outcome on sunitinib in 
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the pivotal trial (PFS 11.0 and OS 26.0 months [1]). This difference is likely due to patient selection: all the 
patients had to complete at least one cycle of sunitinib and had to reach at least the first evaluation by CT scan. 
CONCLUSION 
Polymorphisms in the ABCB1 efflux pump are associated with the incidence of dose reductions in mRCC patients 
treated with sunitinib. Prospective validation of these findings including the association with sunitinib plasma 
levels is warranted and ongoing (EudraCT: 2011-006085-40/MetaSun).  
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TABLE 1A: ANALYZED SNPS LINKED TO SUNITINIB  PHARMACOKINETICS 
 
Polymorphism Number of pts  
Therapy 
Reasons for selection of SNPs for this project 
ABCB1 
rs1128503 
1236C>T 
rs1045642 
3435C>T 
rs2032582 
2677G>T or G>A 
88 pts 
Sunitinib 
Better PFS (19 vs 8 months; p=0.027) and OS (34 vs 21 months; p=0.025) 
in the CC/CT-genotype compared to the TT-genotype in rs1128503 [8]. 
89 pts 
Sunitinib 
Trend to better PFS (HR 1.42; p=0.089) and better OS (HR 1.75; p=0.055) 
in favor of the CC- and CT-genotype in rs1128503 [7]. 
129 pts 
Sunitinib 
Better PFS (15.2 vs 8.4 months; p=0.033) and a tendency for prolonged OS 
(23.9 vs 15.4 months; p=0.078) in presence of a TCG haplotype (rs1045642 
– rs1128503 - rs2032582) in ABCB1 (thus a CC-genotype in rs112503) [6].  
241 pts 
Pazopanib 
Better OS (28 vs 20 months, p=0.009) in the CC-genotype compared to the 
TT-genotype in rs1128503 [11].  
CYP3A5 
rs776746 
6986G>A 
128 pts 
Sunitinib 
Better PFS (not reached vs 9.3 months) for the AA- and AG-genotypes 
compared to the GG-genotypes (p=0.032) [6]. 
84 pts 
Sunitinib 
More dose-reductions (HR 3.75; p=0.022) in the AG-genotype compared to 
the GG-genotype [7]. 
NR1/2  
rs3814055 
25385C>T 
136 pts 
Sunitinib 
Better PFS (10.8 vs 6.7 months; p=0.025) and better OS (17.1 vs 10.2 
months; p=0.017) for the CT- and CC-genotypes compared to the TT-
genotype [6]. 
241 pts 
Pazopanib 
Better OS for the CC-genotype: 29 vs 22 versus 23 months for the CC-, CT- 
and TT-variants respectively (p=0.03) [10]. 
NR1/2 
rs2276707 
8055C>T 
136 pts 
Sunitinib 
Better PFS (10.8 vs 6.7 months) in the CC- and CT-genotypes compared to 
the TT-genotype (p=0.025) [6]. 
83 pts 
Sunitinib 
Better PFS (18 vs 7 months; p=0.047) and trend for better OS (31 vs 12 
months; p=0.08) in the GG- and GT-genotype compared to the TT-genotype 
[8]. 
NR1/3 
rs4073054 
7837T>G 
 
135 pts 
Sunitinib 
Better PFS (13.3 vs 8.0 months) if a CAT-copy was absent in the NR1/3 
haplotype composed of rs2307424, rs2307418 and rs4073054 (thus no TT-
genotype in rs4073054) (p=0.017) [6]. 
87 pts 
Sunitinib 
Better PFS (21 vs 12 months; p=0.025) and OS (35 vs 22 months; p=0.035) 
in the GG- and GT-genotype compared to the TT-genotype [8]. 
SNP: single nucleotide polymorphism. PFS: progression free survival. OS: overall survival. Pts: patients. 
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TABLE 1B: ANALYZED SNPS LINKED TO SUNITINIB  PHARMACODYNAMICS 
 
Polymorphism Number of pts  
Therapy 
Reasons for selection of SNPs for this project 
VEGFR1 
rs9582036 
319A>C 
91 pts 
Sunitinib 
Better PFS (18 vs 10 months; p=0.06) and better OS  (31 vs 14 months; 
p=0.008) in the AA- and AC-genotypes compared to the CC-genotype [9].  
VEGFR3 
rs307826 
1480A>G 
89 pts 
Sunitinib 
Better PFS (13.7 vs 3.6 months; p=0.0079) in the AA-genotype compared to 
the AG-genotype [7]. 
241 pts  
Pazopanib 
OS of 26, 23 and 3.2 months for the AA-, AG- and GG-genotypes, 
respectively (p=0.04) [11]. 
88 pts 
Sunitinib 
Better PFS (19 vs 10 months; p=0.051) and OS (31 vs 22 months; p=0.013) 
in the AA-genotype compared to the AG- and GG-genotype [8]. 
SNP: single nucleotide polymorphism. PFS: progression free survival. OS: overall survival. Pts: patients. 
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TABLE 2: PATIENT CHARACTERISTICS AT DIAGNOSIS OF mRCC AND AT THE START OF SUNITINIB 
TREATMENT 
  
AT INITIAL DIAGNOSIS TOTAL 
Male  72% (69/96) 
Mean age  59 years 
Ethnic origin   Caucasian 95% (91/96) 
  Unknown 5% (5/96) 
Synchronous metastasis 51% (47/93) 
Fuhrman grade 1-3 46% (43/94) 
4  54% (43/94) 
  Clear cell histology  92% (88/96) 
AT THE START OF SUNITINIB  
 ECOG PS >0 42% (40/96) 
   Neutrophils >4.500/mm³ 43% (40/94) 
   Platelets >400.000/mm³ 13% (12/96) 
   Hemoglobin low (<11.5 g/dl (women) or <13 g/dl (men)) 43% (41/96) 
   LDH >1.5 ULN 9% (8/94) 
  Corrected Calcium >10 mg/dl  8% (7/93) 
  Time from nephrectomy to systemic treatment <12 months 63% (90/96) 
   Immunotherapy before sunitinib 25% (24/96) 
   Site of metastasis 
Lung 79% (76/96) 
Liver  20% (19/96) 
 Bone  39% (37/96) 
 Brain 7% (7/96) 
  IMDC prognosis 
Favorable  14% (13/96) 
Intermediate  59% (57/96) 
Poor  27% (26/96) 
ULN: upper limit of normal. ECOG PS: Eastern Cooperative Oncology Group Performance Status. LDH: Lactate 
deshydrogenase. IMDC: International Metastatic Renal Cell Carcinoma Database Consortium.  
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TABLE 3: GENOTYPE AND ALLELE DISTRIBUTION OF SELECTED SNPS 
 
RS ID Polymorphism Location or 
functional 
consequence 
n Wildtype/ 
Wildtype  
n (%) 
Wildtype/ 
Variant  
n (%) 
Variant/ 
Variant 
n (%) 
Observed 
minor allele 
frequency 
(%) 
Minor allele 
frequency 
in  dbSNP 
(%) 
ABCB1  
rs1045642 3435C>T I1154I 96 27 (28) 49 (51) 20 (21) 46.3 53.4 
rs1128503 1236C>T G412G 95 36 (39) 43 (45) 16 (17) 39.5  45.1 
rs2032582 2677G>T or G>A A893S 89 32 (36) 42 (47) 15 (17) 40.5  41.7 
CYP3A5          
rs776746 6986G>A Affecting splicing 88 78 (89) 11 (8) 0 (0) 6.3  3.6 
NR1/2          
rs3814055 25385C>T UTR-5 93 36 (39) 39 (42) 18 (19) 40.3  33.6 
rs2276707 8055C>T Intron 91 60 (66) 25 (27) 6 (7) 20.3  9.3 
NR1/3          
rs2307424 5719C>T P151P 96 49 (51) 37 (39) 10 (10) 29.6  33.6 
rs2307418 7738A>C Intron 96 71 (74) 25 (26) 1 (1) 14.1  15.9 
rs4073054 7837T>G Intron 96 38 (40) 43 (45) 15 (16) 39.1  40.7 
VEGFR1         
rs9582036 319A>C Intron 96 46 (48) 41 (43) 9 (9) 30.7 31.3 
VEGFR3         
rs307826 1480A>G T494A 96 72 (75) 22 (23) 2 (2) 13.5 10.2 
n = number of patients with successful determination of polymorphisms. Note that rs2307424 and rs4073054 in 
NR1/3 were analyzed because of their involvement in the CAT-haplotype [6]. rs2032582 and rs1045642 in 
ABCB1 were analyzed because of their involvement in the TCG-haplotype [6].  
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TABLE 4: UNIVARIATE ANALYSIS: ASSOCIATION BETWEEN SNPS AND TIME OF DOSE REDUCTION 
Gene (a) 
SNP ID 
Polymor-
phism 
Nbr 
of pts 
Median TTDR 
(cycles) 
p (UV) HR 95%CI of HR 
ABCB1 
rs1128503 
1236C>T 
CT+CC 73 7 0.031 2.278 1.077 – 4.820 
TT 15 19 
ABCB1 
rs1045642 
3435C>T 
 
CC 27 12 0.26 
 
NA NA 
CT 49 7 
TT 20 19 
CC+CT 76 9 0.47 NA NA 
TT 20 19    
ABCB1 
rs2032582 
2677G>T or G>A 
GG 32 11 0.048 
 
NA NA 
GT/GA 42 5 
TT/TA 15 19 
GG+GT/GA 74 7 0.046 2.106 1.015 – 4.371 
TT/TA 15 19    
CYP3A5 
rs776746 
6986G>A 
GG 78 9 0.23 NA NA 
AG 10 NR 
NR1/2 
rs3814055 
25385C>T 
CC+CT 75 10 0.35 NA NA 
TT 18 5 
NR1/2 
rs2276707 
8055C>T 
CC+CT 85 7 0.027 2.954 1.132 – 7.707 
TT 6 41.5 
NR1/3 
rs2307424 
5719C>T 
CC 49 11 0.90 NA NA 
CT+TT 47 7 
NR1/3 
rs2307418 
7738A>C 
AA 71 10 0.92 
 
NA NA 
AC+CC 25 7 
NR1/3 
rs4073054 
7837T>G 
TT 38 7 0.92 NA 
 
NA 
 TG+GG 58 9 
VEGFR1 
rs9582036 
319A>C 
AA+AC 87 9 0.46 NA NA 
CC 9 5    
VEGFR3 
rs307826 
1480A>G 
AA 72 9 0.85 NA NA 
AG+GG 24 9    
p-values were calculated by a log-rank test. TTDR: time-to-dose-reduction. UV: univariate analysis. NA: not 
applicable. HR: hazard ratio. 95%CI: 95% confidence interval. 
For ABCB1 rs1128503, we analyzed genotype TT against and the combination of genotype CC and CT, because 
four previous publications clearly associated the TT-variant with poor outcome. For ABCB1 rs1045642 and 
rs2032582, we analyzed the three genotypes separately and then combined the genotypes in function of the 
obtained graphs, isolating the groups that were associated to the longest TTDR. In case of CYP3A5, there were 
no AA-variants in our series. For NR1/2, the variants were combined as it was done in the original publications 
isolating the patients with TT-genotype, associated with poorer outcome. For NR1/3 rs2307424, the analysis of 
the three genotypes separately did not result in a significant difference in TTDR. We report the combination of the 
genotypes as it was done in previous publications. For NR1/3 rs2307418, there was only one patient with the CC-
genotype. For NR1/3 rs4073054, we compared the TT-genotype to the TG- and GG-genotype because the TT-
genotype was associated to poorer survival. For VEGFR1 rs9582036, the genotypes were pooled as it was done 
in the original publication. For VEGFR3 rs307826, there were only 2 patients with the GG-genotype: they were 
pooled with the GA-genotype patients. 
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FIGURE 1: IMPACT OF ABCB1 rs1128503 VARIANTS ON TIMING OF DOSE REDUCTIONS 
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FIGURE 2: IMPACT OF ABCB1 rs2032582 VARIANTS ON DOSE REDUCTIONS 
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FIGURE 3: IMPACT OF NR1/2 rs2776707 VARIANTS ON DOSE REDUCTIONS 
0 5 10 15 20 25 30 35 40 45 50 55 60
0
10
20
30
40
50
60
70
80
90
100
CC+CT: 7 cycles
Time (cycles sunitinib)
TT: 41.5 cycles
p=0.027
Time-to-dose-reduction and rs2276707 in NR1/2
Cycles of sunitinib 0 3 6 9 12 15 18 21 
Subjects without dose reduction (CC+CT) 85 68 35 18 10 5 4 3 
Subjects without dose reduction (TT) 6 6 4 3 3 2 2 2 
 
 
 
FIGURE 4: IMPACT OF ABCB1 rs1128503 VARIANTS ON PROGRESSION FREE SURVIVAL  
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FIGURE 5: IMPACT OF ABCB1 rs1128503 VARIANTS ON OVERAL SURVIVAL 
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PART 5: VEGFR1 SINGLE NUCLEOTIDE POLYMORPHISMS ASSOCIATED WITH OUTCOME IN PATIENTS 
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PART 6: PROGNOSTIC IMPACT OF BASELINE SERUM C-REACTIVE PROTEIN IN METASTATIC RENAL 
CELL CARCINOMA PATIENTS TREATED WITH SUNITINIB. 
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ABSTRACT  
 
Purpose 
 
To assess the efficacy of anti-vascular endothelial growth factor receptor tyrosine kinase inhibitors (anti-VEGFR-
TKIs) in patients with metastatic clear cell renal cell carcinoma (m-ccRCC) with sarcomatoid dedifferentiation.  
 
Patients and methods  
 
We retrospectively reviewed the files of all m-ccRCC patients consecutively treated with first-line anti-VEGFR-
TKIs at our institution. Pathology slides from nephrectomy and metastasectomy were assessed for the presence 
and extent of sarcomatoid dedifferentiation.  
 
Results  
 
One hundred and twenty-four patients were included: nephrectomy and metastasectomy specimens were 
available in 117 and 35 patients, respectively. Thirty percent of the primary nephrectomy specimens had 
sarcomatoid features and the median involvement of the sarcomatoid component was 21% (range: 1-95%). 
Patients with an important sarcomatoid component, defined as >25% involvement of the tumour, had a very poor 
outcome: progression-free survival (PFS) and overall survival (OS) were 3 and 6 months, respectively, and no 
partial responses (PR) were observed. Patients without sarcomatoid dedifferentiation or sarcomatoid involvement 
<25% had a PFS of 12 months (p<0.0001; HR 51, 95%CI 12.58-207.3), an OS of 22 months (p<0.0001, HR 
10.72, 95%CI 3.56-32.25) and a PR rate of 50% (p=0.0015). Patients with a sarcomatoid component >25% in the 
metastasectomy also had a poorer PFS and OS on anti-VEGFR-TKIs compared to patients with <25% of 
sarcomatoid features at these sites. 
 
Conclusion  
 
m-ccRCCs-patients with tumours containing a component of sarcomatoid dedifferentiation of >25% of the total 
tumour volume have a very poor outcome when treated with anti-VEGFR-TKIs. Analysis of the extent of 
sarcomatoid features in resected metastases can provide additional prognostic information. 
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INTRODUCTION 
 
At initial diagnosis, up to one-third of renal cell carcinoma (RCC) patients present with metastatic disease and 
40% of primary non-metastatic patients, who undergo a nephrectomy with curative intent, will ultimately relapse or 
develop metastases [1]. Therapies targeting the VEGF-pathway (the TKIs sunitinib, sorafenib, pazopanib and 
axitinib, and the monoclonal antibody bevacizumab) or inhibiting the mammalian target of rapamycin pathway 
(everolimus and temsirolimus), have almost completely replaced cytokines as first- and second-line treatment of 
metastatic RCC (mRCC). 
In the pivotal trial in previously untreated m-ccRCC patients, half of the patients treated with sunitinib experienced 
a PR, 43% stable disease (SD), and 7% progressive disease (PD) at first evaluation. Median PFS and OS were 
11 and 26.4 months, respectively [2-3]. In the sorafenib pivotal trial in m-ccRCC patients pre-treated with 
cytokines, 10% of patients achieved a PR, 74% SD and 16% early PD with a median PFS and OS of 5.5 and 17.8 
months, respectively [4]. In previously untreated predominantly ccRCC patients, pazopanib showed a median 
PFS of 11.1 months, and 33% of PR, 42% of SD and 16% of early PD as best response [5]. Despite this major 
breakthrough in the treatment of mRCC, eventually all patients will relapse due to acquired secondary resistance. 
Several mechanisms of resistance have been proposed, but reliable biomarkers predictive of anti-VEGFR-TKI 
sensitivity or primary/secondary resistance are still lacking [6]. Baseline serum lactate dehydrogenase (LDH), 
haemoglobin, corrected calcium, neutrophil, platelet and C-reactive protein (CRP) levels, bone metastases, the 
number of metastatic sites, prior nephrectomy, Eastern Cooperative Oncology Group Performance Status (ECOG 
PS) and the interval between diagnosis and systemic therapy were shown to be associated with PFS and/or OS 
in mRCC treated with anti-VEGF-targeted therapy [7-10].  
RCCs of all histological subtypes can present with sarcomatoid dedifferentiation, a growth pattern characterized 
by variable degrees of spindle-shaped cell histology [11-12]. Most sarcomatoid RCCs presents as a bi-phasic 
lesion with both mesenchymal (sarcoma-like) and epithelial (carcinoma) elements, rarely the sarcomatoid 
dedifferentiation affects the whole tumour. Sarcomatoid dedifferentiation is associated with a more aggressive 
disease and poor outcome after nephrectomy or on immunotherapy. 
The two major trials that defined the benefit of anti-VEGFR-TKIs included patients with clear cell histology [2] or 
predominantly clear cell histology [5], but did not provide details on the percentage of tumours displaying 
sarcomatoid elements, nor on the percentage of sarcomatoid involvement of the tumours. In two retrospective 
series with mRCC-patients with sarcomatoid dedifferentiation, PRs on VEGF-targeted therapies were seen, but 
outcome seemed globally poorer than in mRCC-patients without sarcomatoid dedifferentiation, although a direct 
comparison was lacking [13-14]. Moreover, both series included also non-ccRCCs, in which anti-VEGFR-TKIs are 
less active [15-16].  
We aimed to study the impact of sarcomatoid dedifferentiation on outcome on anti-VEGFR-TKIs in clear cell RCC 
in the metastatic setting. 
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METHODS 
 
In the database of the University Hospitals Leuven, we searched for patients with m-ccRCC treated with sunitinib, 
sorafenib or pazopanib as first-line anti-VEGFR-TKIs between November 2005 and August 2013 and with 
available tissue blocks or representative slides from nephrectomy or metastasectomy specimens. Patients in 
whom only biopsies were available, were not considered for inclusion.  
In these patients, anti-VEGFR-TKIs were started at the labelled dose: 50 mg/day 4 weeks on 2 weeks off for 
sunitinib and 800 mg/day continuously for sorafenib and pazopanib. Previous immunotherapy or chemotherapy 
was allowed, but previous targeted therapy was prohibited. The study was approved by the Ethics Committee of 
our institution. Signed consent was obtained from all patients. In some cases, we used biologic material and 
clinical data from patients who had already died and for whom a general positive advice for the utilization of 
remaining tissue was foreseen by the institutional board. 
The following clinical data were assessed: patient age at diagnosis, gender, prior treatment, baseline Karnofsky 
PS, number and sites of metastases (bone, liver, lung, lymph nodes), platelet count, neutrophil count, LDH level, 
haemoglobin, corrected calcium, C-reactive protein, and time between nephrectomy and start of systemic 
treatment. Patients underwent follow up CT-scans (chest and abdomen) every 2 to 3 months during TKI 
treatment.  
All available pathology slides were reviewed by an expert genitourinary pathologist (E.L.) blinded to patient 
outcome. The classification of RCC subtypes and the presence of sarcomatoid dedifferentiation were assessed 
following the 2004 WHO Classification of Renal Tumours. The percentage of sarcomatoid elements in each 
nephrectomy or metastasectomy sample compared to the total available tumour extent was estimated by 
examining every slide from each case individually. The area of the sarcomatoid component relative to the tumour 
or metastasis was estimated on each slide. The mean percentage of sarcomatoid component relative to the 
tumour or metastasis from each slide was added to obtain the total estimated sarcomatoid percentage for each 
patient. Samples with sarcomatoid dedifferentiation in the original tumour were classified Fuhrman grade 4 by 
definition, because sarcomatoid dedifferentiation is believed to represent transformation of the RCC to higher 
grade.  
Endpoints of the study were PFS, OS and RR. We defined PFS as the time between the first day on sunitinib and 
the date of radiological progressive disease or death. Patients who had not progressed at database closure were 
censored at last follow-up. OS was defined as the time between the first day on sunitinib and the date of death or 
last date of follow-up. An objective response was defined according to Response Criteria in Solid Tumours 
(RECIST 1.0). Patients who had PD at the first CT-scan evaluation were considered as early PD patients. 
Patients who stopped therapy for toxicity before reaching the first evaluation by CT-scan were discarded. PFS 
and OS distributions were estimated using the Kaplan-Meier product-limit method. p-values were calculated with 
the log rank Mantel-Cox test. The association between the sarcomatoid component and outcome was studied by 
a Cox proportional hazards model in order to obtain an optimal cut-off for OS.  
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RESULTS 
 
One hundred and twenty four patients cases were available for this study including nephrectomy specimens in 
117 and metastasectomy specimens in 35 patients. In 28 patients, both nephrectomy and metastasectomy 
specimens were available. Median follow-up of the 124 patients was 63 months (range 1-96) as calculated from 
the start of first-line anti-VEGFR-TKI.  
 
Analysis of the sarcomatoid component in 117 primary nephrectomy specimens 
 
One hundred and seventeen patients were included in this analysis. Patient characteristics are shown in Table 1. 
Overall RR was 45% and median PFS and OS were 9 and 18 months, respectively. The mean number of slides 
reviewed for each patient was 4.95 (range: 1-16). Sarcomatoid dedifferentiation was observed in 35 patients 
(30%) (Table 2). In tumours with sarcomatoid dedifferentiation, the median percentage of the sarcomatoid 
component compared to the total available tumour extent was 21% (range: 1%-95%).  
When comparing patients with tumours with sarcomatoid dedifferentiation to those without sarcomatoid 
dedifferentiation, we did not find any statistically significant difference in PFS or OS (HR 1.16 95%CI 0.72-1.88 
both for PFS and OS), although there were more early PD patients in the group with sarcomatoid dedifferentiation 
(34% versus 11%, p=0.003 by Fisher exact).  
Nevertheless, in a continuous analysis of the impact of the percentage of sarcomatoid dedifferentiation with Cox 
regression, the presence of a sarcomatoid component was associated with outcome  (PFS: HR 22.5 (95%CI 6.8-
73.8); p<0.0001 and OS: HR 15.4 (95%CI 4.8-49.8); p<0.0001)) and a threshold of <25% versus >25% was 
determined as the best cut-off value for OS. In patients with >25% of sarcomatoid dedifferentiation, PFS (3 versus 
12 months; p<0.0001; HR 51 (95%CI 12.58-207.3)) and OS (6 versus 22 months; p<0.0001; HR 10.72 (95%CI 
3.56-32.25)) were significantly shorter than in patients with <25% of sarcomatoid dedifferentiation. In patients with 
a sarcomatoid component >25%, we did not observe any PR, while in the group with a sarcomatoid component 
<25%, we noticed 50 % of PR (p=0.0015). PD was significantly more frequent (64% versus 13%; p<0.0001) in 
patients with a sarcomatoid component >25% than in patients with a sarcomatoid component <25%. PRs were 
frequently observed in patients (16 out of 24 (67%)) with a sarcomatoid component between 1% and 24%. Figure 
1 illustrates the impact of the threshold of <25% versus >25% of sarcomatoid dedifferentiation on PFS and OS.  
At start of TKIs, compared to patients with tumours with a sarcomatoid dedifferentiation <25% (Table 4), patients 
with a sarcomatoid component >25% had more often a poor International Metastatic Renal Cell Carcinoma 
Database Consortium (IMDC) prognostic score, a lower Karnofsky PS, a higher incidence of anaemia, a higher 
baseline platelets count and a higher baseline CRP plasma level.  
Seventy four percent (26/35) of the patients with sarcomatoid dedifferentiation (any percentage of component) 
started systemic therapy within one year after initial diagnosis of RCC. The median time from diagnosis to 
systemic treatment in patients with sarcomatoid dedifferentiation (any percentage of component) was 6 months.  
Table 3 reports an overview of all established prognostic criteria assessed in our series in univariable analysis 
and the outcome of the multivariable Cox regression analysis. The presence of a sarcomatoid component >25% 
of the tumour was found to be an independent prognostic factor for PFS and OS with hazard ratios of 4.446 
(95%CI 2.084-9.486) and 2.885 (95%CI 1.380-6.028), respectively. Parameters that were taken into account for 
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the multivariable analysis were: baseline neutrophil and platelets count, baseline haemoglobin, corrected calcium, 
LDH and CRP levels, Karnofsky PS, and the presence of bone and liver metastases. 
 
Analysis of the sarcomatoid component in 35 metastasectomy  specimens 
 
Thirty-five patients were included in this analysis. In all cases, the metastasectomy occurred before the start of 
anti-VEGFR-TKIs. In 14 of these 35 patients (40%), sarcomatoid features were present in the metastasis (Table 
2). In four patients with two metastasectomy specimens, the percentage of sarcomatoid dedifferentiation was 
identical in both metastases. Patients (n=6)  with a sarcomatoid component >25% in the metastasectomy 
specimen had a very short PFS (2.5 versus 23 months; p=0.0007; HR 0.04 (95%CI 0.007-0.26)) and OS (12.5 
versus 31 months; p=0.0076; HR 0.14 (95%CI 0.036-0.60)) compared to patients (n=29) with a sarcomatoid 
component <25% (Figure 2).  
 
Comparison of sarcomatoid features in the primary nephrectomy and the metastasectomy specimen 
 
Twenty-eight patients were included in this analysis. Table 4 shows the comparison of the sarcomatoid 
component in the primary tumour and in the resected metastases. Twenty-six of these 28 patients had a 
sarcomatoid component of <25% in the primary tumour. Three of these 26 patients had a sarcomatoid component 
of >25% in the resected metastases. These three patients had a remarkably poor PFS (3 versus 26 months; 
p=0.0004; HR 0.006 (95%CI 0.00-0.10)) and OS (5 versus 31 months; p=0.0009; HR 0.01 (95%CI 0.00-0.16)) on 
anti-VEGFR-TKIs compared to patients with <25% of sarcomatoid features both on the primary nephrectomy 
specimen and on the resected metastases (Figure 3).  
 
DISCUSSION 
 
The aim of this study was to describe the correlation between the presence of a sarcomatoid component in 
ccRCC and outcome on anti-VEGFR-TKIs in metastatic disease. We identified a subgroup of patients with an 
important component of sarcomatoid features (>25% of the initial tumor) with very poor outcome when treated 
with sunitinib, sorafenib or pazopanib. On the opposite, the outcome of patients with tumors with a limited 
component of sarcomatoid dedifferentiation (<25% of the initial tumor volume) was equivalent to the outcome of 
patients with tumors without sarcomatoid features. 
 
Our data confirm the association between the presence of a sarcomatoid component and a more aggressive 
clinical course of the disease. Prior to the era of anti-VEGF-targeted therapy, patients with localized sarcomatoid 
tumours had 2- and 5-year survival rates of only 25%-40% and 19%, respectively [17-18]. In the metastatic 
setting, median OS was only 3-10 months from the time of diagnosis [19-21]. Some studies reported an 
association between a higher proportion of sarcomatoid dedifferentiation in the primary kidney tumour and worse 
survival [18-19] but others did not confirm this observation [20, 22-24]. RCCs with sarcomatoid dedifferentiation 
tend to metastasize earlier: on 34 nephrectomy specimens, Tickoo et al. reported a significant association 
between the importance of the sarcomatoid component in the tumour and the incidence of synchronous or 
metachronous metastases [19]. At the era of anti-VEGF-targeted therapy, Golshayan et al. reported a median 
time from diagnosis to treatment of 7 months in mRCCs with sarcomatoid features. Seventy percent of these 
patients were diagnosed within 1 year from starting therapy [13].  
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RCCs with sarcomatoid features have historically demonstrated limited sensitivity to chemotherapy or 
immunotherapy. Retrospective reviews and a few prospective trials have involved limited patient numbers with 
disappointing results. On a series of 10 patients with mRCCs with sarcomatoid dedifferentiation treated with 
doxorubicin and gemcitabine, Nanus et al. reports five patients with early PD, two with SD and three PRs [25]. 
The largest published prospective clinical trial on 23 sarcomatoid RCCs treated with doxorubicin and ifosfamide 
reported no objective responses and a median PFS and OS of 2.2 and 3.9 months, respectively [26].  
 
In patients treated with radical nephrectomy for RCC, incidences of sarcomatoid features of 5% to 8% were 
reported [18, 22, 23]. The higher incidence of sarcomatoid dedifferentiation in our series of primary nephrectomy 
specimens (30%) is probably explained by the fact that all our patients developed later in the course of the 
disease or together with the primary tumour distant metastasis requiring systemic therapy. RCCs with 
sarcomatoid features are more likely to relapse after initial nephrectomy compared to RCCs without sarcomatoid 
dedifferentiation.  
 
Concerning the relative importance of the sarcomatoid component in each tumour, we found a similar percentage 
of sarcomatoid dedifferentiation (21% (range 1-95%)) as Golshayan et al. (14% in a series of 43 patients (range 
3%-90%))  [13] and Molina et al. (20% in a series of 63 patients (range 2%-100%)) [14]. Both of these series 
involved patients who were treated in the metastatic setting with systemic therapy. 
 
In literature, two studies indicate that patients with sarcomatoid mRCC (detected on the primary tumour) treated 
with anti-VEGF-targeted therapy can benefit from the therapy, although outcome seems to be poorer than in 
patients without sarcomatoid dedifferentiation. Golshayan et al. published the largest (n=43) series on outcome in 
sarcomatoid mRCC treated with sunitinib (49%), sorafenib (28%), bevacizumab (19%) or bevacizumab and 
sunitinib (5% of patients). PR was observed in 19%, SD in 49% and early PD in 33% of patients. Median PFS and 
OS were 5.3 and 11.8 months, respectively. PRs were confined to patients with tumours with <20% of 
sarcomatoid elements. Early PD was observed in only 22% of these patients, while early PD presented in 56% of 
the patients who had >20% of sarcomatoid elements. The differences in PFS (6.8 versus 4.3 months) and OS 
(14.9 versus 8.6 months) favoured the group that had <20% of sarcomatoid elements, but these differences were 
not statistically significant [13]. Molina et al. reported on 32 patients treated with first-line sunitinib (29 patients) or 
sorafenib (3 patients). Of the patients treated with sunitinib, 14% had a PR, 59% had SD and 28% PD as best 
response. Median PFS and OS under sunitinib were 4.4 and 10 months respectively [14]. In opposition to our 
series, the series Golshayan et al. and Molina et al. did not include a control group of patients without 
sarcomatoid dedifferentiation. Moreover, patients with non-ccRCCs, in which anti-VEGFR-TKIs are less efficient, 
were included in both series. 
 
We found a similar incidence of sarcomatoid features in metastasectomy specimens as in the primary tumour, but 
sarcomatoid features were not always stable during the course of the disease. Shuch et al. also compared 
sarcomatoid aspects in primary nephrectomy and metastasectomy specimens in 32 patients and also reported an 
evolution of the importance of sarcomatoid features [27]. We are the first to show an association between the 
importance of the sarcomatoid component in the metastasectomy specimen and outcome on anti-VEGFR-TKIs. 
The study of associations between outcome and characteristics of metastases rather than of the primary tumour 
is of interest, because in the metastatic setting, response to therapy is usually determined on metastatic sites.  
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The underlying mechanism of resistance of sarcomatoid tumours to anti-VEGF-targeted therapy is unknown, but 
epithelial-to-mesenchymal transition (EMT) could be involved [28-29]. EMT can occur in several cancer types, 
including RCCs, and is characterized by the acquisition of a sarcomatoid phenotype with spindle cells and the 
gradual loss of an epithelial phenotype. Down regulation of micro-RNA-141 was shown to be associated with 
sarcomatoid features and sunitinib resistance through the induction of EMT and hypoxia resistance [30]. In 
hepatocellular carcinoma, in vitro experiences  have shown that after long-term exposure to sorafenib, resistant 
cells changed morphologically into spindle shaped cells and showed loss of cell-to-cell contacts, typical features 
of EMT [31].  
 
Nevertheless, for several reasons anti-VEGF-targeted therapy could remain partially active in RCCs with 
sarcomatoid features. Anti-VEGF-targeted therapy can be active on the non-sarcomatoid component of the 
tumour, inducing tumour shrinkage. EMT is partially reversible and hypoxia-induced pathway markers, as 
observed by immunohistochemical staining, continue to be over-expressed in sarcomatoid ccRCCs both in the 
epithelial and in the sarcomatoid component [19].  
 
We noticed a high level of Fuhrman grade 4 tumors in our series: 61% in the total series and 57% in the subgroup 
with sarcomatoid dedifferentiation <25% of the tumor volume. This high incidence is probably due to the fact that 
the pathologist looked specifically for sarcomatoid dedifferentiation in the samples. Even tumors with a very 
limited sarcomatoid component were classified Fuhrman grade 4 by definition. 
Our study has two limitations. In patients with few available slides, the percentage of sarcomatoid dedifferentiation 
might be underestimated. Additionally, given the low number of patients in our study, these findings should be 
validated in a larger patient series. 
 
CONCLUSION 
 
We studied the impact of sarcomatoid dedifferentiation in primary nephrectomy specimens on treatment outcome 
in m-ccRCC treated with anti-VEGFR-TKIs. We identified a subgroup of patients with an important component of 
sarcomatoid features (>25% of the initial tumour) with very poor outcome when treated with sunitinib, sorafenib or 
pazopanib. Other treatment options should be considered, ideally within clinical trials. Pathologists should not only 
communicate the presence of sarcomatoid features in RCC resection specimens, but also report the percentage 
of tumour involvement by the sarcomatoid component. Finally, the presence of sarcomatoid features at metastatic 
sites can provide additional prognostic information.  
 
 
SHORT CLINICAL PRACTICE POINTS SECTION 
 
 Metastatic ccRCC-patients with an important component of sarcomatoid features (>25% of the initial 
tumour) have a very poor outcome when treated with sunitinib, sorafenib or pazopanib. Other treatment 
options should be considered, ideally within clinical trials.  
 Pathologists should not only communicate the presence of sarcomatoid features in RCC resection 
specimens, but also report the percentage of tumour involvement by the sarcomatoid component.  
 The presence of sarcomatoid features at metastatic sites can provide additional prognostic information. 
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TABLE 1: INCLUDED PATIENTS WITH AVAILABLE PRIMARY NEPHRECTOMY 
SPECIMEN (117) 
  
PATIENT CHARACTERISTICS AT INITIAL 
DIAGNOSIS 
TOTAL Sarcomatoid 
component <25% 
Sarcomatoid 
component >25% 
p (*) 
Number of patients  117 91% (106/117) 9% (11/117)  
Mean age (years)  59 59 59  
Male  66% (77/117) 65% (69/106) 73% (8/11) 0.6 
Metastases at initial diagnosis 50% (58/117) 47% (50/106) 73% (8/11) 0.1 
Fuhrman (**) Grade 1-3 39% (46/117) 43% (46/106) 0% (0/11) 0.005 
Grade 4  61% (71/117) 57% (60/106) 100% (11/11)  
PATIENT CHARACTERISTICS AT START OF TKI    
Karnofsky <80  14% (16/117) 11% (12/106) 36% (4/11) 0.02 
   Neutrophils >4.500/mm³ 51% (60/117) 50% (53/106) 64% (7/11) 0.4 
   Platelets >400.000/mm³ 14% (16/117) 11% (12/106) 36% (4/11) 0.02 
   Hemoglobin <11.5 g/dl (women) or <13 g/dl (men) 47% (55/117) 42% (45/106) 91% (10/11) 0.003 
   LDH > 1.5x ULN 5% (6/117) 6% (6/106) 0% (0/11) 0.4 
   Corrected calcium > 10 mg/dl 25% (29/117) 23% (24/106) 45% (5/11) 0.1 
   CRP > 5 mg/l 75% (88/117) 73% (77/106) 100% (11/11) 0.046 
   Time nephrectomy to systemic treatment <12 months 50% (58/117) 49% (52/106) 55% (6/11) 0.7 
   Immunotherapy before TKI  38% (45/117) 39% (41/106) 36% (4/11) 0.9 
   Site of  metastasis 
Lung 77% (90/117) 76% (81/106) 82% (9/11)  0.7 
Liver 21% (24/117) 20% (21/106) 27% (3/11) 0.6 
 Brain 7% (8/117) 6% (6/106) 18% (2/11) 0.1 
 Bone 42% (49/117) 42% (44/106) 45% (5/11) 0.8 
 Mean number 2.93 2.91 3.18  
IMDC prognosis 
 
Favourable  11% (13/117) 12% (13/106) 0% (0/11) 0.2 
Intermediate  51% (60/117) 55% (58/106) 18% (2/11) 0.02 
Poor  38% (44/117) 33% (35/106) 82% (9/11) 0.002 
FIRST-LINE TKI      
Sunitinib 71% (83/117) 70% (74/106) 82% (9/11) 0.4 
Sorafenib 18% (21/117) 20% (21/106) 0% (0/11) 0.1 
Pazopanib 11% (13/117) 10% (11/106) 18% (2/11) 0.4 
NA: Not applicable. ULN : Upper limit of normal. TKI : Tyrosine kinase inhibitor. IMDC : International metastatic 
renal cell carcinoma database consortium.  
(*) P-values were obtained by Fisher Exact test for comparison of percentages.  
(**) All samples with sarcomatoid dedifferentiation were classified Fuhrman grade 4. 
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TABLE 2: INCIDENCE OF SARCOMATOID DEDIFFERENTIATION  
 
SARCOMATOID 
 INVOLVEMENT 
n (%) 
PRIMARY TUMOUR 
n (%) 
METASTASECTOMY 
p-value 
No sarcomatoid dedifferentiation  82/117 (70%) 21/35 (60%) 0.26 
Sarcomatoid dedifferentiation  35/117 (30%) 14/35 (40%)  
1-10%  23/117 (20%) 6/35 (17%)  
11-24%  1/117 (1%) 2/35 (6%)  
25-50% 5/117 (4%) 4/35 (11%)  
>50-100%  6/117 (5%) 2/35 (6%)  
>25%  11/117 (9%) 6/35 (17%) 0.15 
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TABLE 3: UNIVARIATE AND MULTIVARIATE ANALYSIS FOR PREVIOUSLY 
DESCRIBED PROGNOSTIC FACTORS IN THE SERIES OF 117 NEPHRECTOMIES  
 
UNIVARIATE ANALYSIS PFS 
(months) 
p-value (*) OS 
(months) 
p-value (*) 
Sarcomatoid 
dedifferentiation 
<25% (n=106) 12 <0.0001 22 <0.0001 
>25% (n=11) 3 6 
Continuous analysis  <0.0001 
HR 22.5 
(6.8-73.8) 
 <0.0001 
HR 15.4 
(4.8-49.8) 
Baseline 
neutrophils 
<4.500/mm³ (n=57) 14 0.02 22 0.03 
>4.500/mm³ (n=60) 6 14 
Baseline serum 
calcium 
<10 mg/dl (n=88) 9 0.6 20 0.19 
>10 mg/dl (n=29) 9.5 11 
Baseline 
hemoglobin 
>11.5 g/dl in women / >13.0 g/dl 
in men (n=62) 
15 0.0005 29 <0.0001 
<11.5 g/dl in women / <13.0 g/dl 
in men (n=55) 
5 9 
Baseline platelet 
count 
<400.000 (n=101) 11 0.008 20 0.01 
>400.000 (n=16) 3 7 
Baseline lactate 
dehydrogenase 
<1.5x ULN (n=111) 11 0.009 20 0.01 
>1.5x ULN (n=6) 2 4 
Baseline CRP <5 mg/l (n=29) 27 <0.0001 31 <0.0001 
 >5 mg/l (n=88) 6  12  
Interval diagnosis 
to systemic 
treatment   
<12 months (n=58) 8 0.7 20 0.9 
>12 months (n=59) 9 18 
Baseline 
Karnofsky PS 
>80 (n=101) 11 0.004 22 0.0009 
<80 (n=16) 3 5 
Presence of bone 
metastases 
No (n=68) 10 0.4 20 0.07 
Yes (n=49) 9 18 
Presence of liver 
metastases 
No (n=93) 11 0.008 22 0.008 
Yes (n=24) 3  6.5  
IDMC 
prognostic 
score 
Favorable (n=13) 17 0.0006 35 <0.0001 
Intermediate (n=60) 14  26 
Poor (n=46) 4  6.5 
TKI Sunitinib (n=83) 12 0.4 18 0.8 
 Sorafenib (n=21) 5  12  
 Pazopanib  (n=13) 7  10  
MULTIVARIATE ANALYSIS FOR PFS p-value Hazard Ratio 95%CI 
Sarcomatoid dedifferentiation 0-<25% versus >25% <0.0001 4.446 2.084 9.486 
Baseline CRP <5mg/l versus >5mg/l 0.006 2.321 1.268 4.249 
MULTIVARIATE ANALYSIS FOR OS     
Sarcomatoid dedifferentiation 0-<25% versus >25% 0.005 2.885 1.380 6.028 
Baseline CRP <5mg/l versus >5mg/l 0.011 2.263 1.202 4.262 
ULN: upper limit of normal. CRP: C-reactive protein. Karnofsky PS: Karnofsky performance status. IMDC : 
International metastatic renal cell carcinoma database consortium. TKI: tyrosine kinase inhibitor. PFS: 
progression-free survival. OS: overall survival. HR: Hazard Ratio. 95%CI: 95% Confidence Interval. (*) Log-rank 
comparison between Kaplan-Meier curves. 
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TABLE 4: COMPARISON OF THE SARCOMATOID COMPONENT BETWEEN THE 
PRIMARY KIDNEY TUMOUR AND THE RESECTED METASTASES 
 
Patient Sarcomatoid 
component on 
nephrectomy 
Sarcomatoid 
component on 
metastasectomy 
Organ of 
metastasectomy 
Evolution of the 
sarcomatoid component 
1+2+3 0% 0% Bone Stable low 
4+5 0% 0% Skin Stable low 
6 0% 0% Lymph node Stable low 
7 0% 0% Gallbladder Stable low 
8+9 0% 0% Lung Stable low 
10+11 0% 0% Pancreas Stable low 
12+13 0% 0% 
0% 
Adrenal 
Lung 
Stable low 
14 0% 0% 
0% 
Lung 
Thyroid 
Stable low 
15 0% 1% Skin Stable low 
16 0% 1% Liver Stable low 
17 0% 1% Bone Stable low 
18 1% 0% Lymph node Stable low 
19 1% 0% 
0% 
Bone  
Adrenal 
Stable low 
20 0% 5% Lung Stable low 
21 5% 0% Duodenum Stable low 
22 10% 5% Local relapse Stable low 
23 0% 20% Parietal Stable low 
24 0% 30% Gingiva Up 
25 0% 100% Liver Up 
26 0% 50% Bone Up 
27 25% 90% Gingiva Stable high 
28 60% 0% Lung Down 
NOTE: “Stable low” indicates that the sarcomatoid component is <25% in both the primary nephrectomy as in the 
metastasectomy specimen. “Stable high” indicates that in both samples, the sarcomatoid component is >25%. 
“Up” means that the sarcomatoid component was <25% in the primary nephrectomy specimen and >25% in the 
metastasectomy. “Down” indicates that the sarcomatoid component was >25% in the primary nephrectomy 
specimen and <25% in the metastasectomy. 
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FIGURE 1: Impact of sarcomatoid dedifferentiation in 117 primary nephrectomy 
specimens on progression-free-survival and overall survival  
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0% Sarcomatoid component: mPFS 11 months
1-<25% Sarcomatoid component: mPFS 14 months
>25% Sarcomatoid component: mPFS 3 months
p<0.0001
         
Months 0 6 12 18 24 30 36 42 
No sarcomatoid component 82 61 35 26 18 11 9 6 
Sarcomatoid component 1-<25% 24 14 12 9 8 6 3 2 
Sarcomatoid component >25% 11 0 0 0 0 0 0 0 
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p=0.0002
             
Months 0 6 12 18 24 30 36 42 48 54 60 66 
No sarcomatoid component 82 68 54 43 32 23 13 10 8 6 6 5 
Sarcomatoid component 1-<25% 24 19 13 11 10 8 6 3 3 3 3 2 
Sarcomatoid component >25% 11 6 2 0 1 1 0 0 0 0 0 0 
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FIGURE 2: Impact of sarcomatoid dedifferentiation in 35 metastasectomy specimens 
on progression-free-survival and overall survival  
 
0 6 12 18 24 30 36 42 48 54 60
0
10
20
30
40
50
60
70
80
90
100PFS (%)
Time (months)
Sarcomatoid component 0-<25%: mPFS 23 months
Sarcomatoid component >25%: mPFS 2.5 months
p=0.0007
         
Months 0 6 12 18 24 30 36  
Sarcomatoid component 0-<25% 29 22 18 14 10 7 4  
Sarcomatoid component >25% 6 1 0 0 0 0 0  
 
HR 0.04 (95%CI 0.007-0.26)
 
 
0 6 12 18 24 30 36 42 48 54 60 66 72 78
0
10
20
30
40
50
60
70
80
90
100
OS (%)
Time (months)
Sarcomatoid component 0-<25% mOS 31 months
Sarcomatoid component >25% mOS 12.5 months
p=0.0076
           
Months 0 6 12 18 24 30 36 42 48 54 
Sarcomatoid component 0-<25% 29 25 20 19 16 14 9 4 4 3 
Sarcomatoid component >25% 6 4 3 3 1 1 0 0 0 0 
 
HR 0.14 (95%CI 0.036-0.60)
138 
 
FIGURE 3: Impact of the importance of sarcomatoid dedifferentiation (0-<25% versus 
>25%) in the metastasectomy specimen (M) in 26 patients without or with limited 
sarcomatoid features (0-<25%) in the primary tumour (T)  
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MOLECULAR SUBTYPES OF CLEAR CELL RENAL CELL CARCINOMA ARE PREDICTIVE OF RESPONSE 
TO SUNITINIB IN THE METASTATIC SETTING 
 
We are currently working on the definitive manuscript of the results of this part of our work. Therefore, in 
this thesis manuscript, we only give a summary of our most important findings.  
 
The objective of this part of our project was to identify new predictive molecular markers for outcome in m-ccRCC 
patients treated with sunitinib, through a multi-omics analysis (mRNA-expression, genome and methylome) 
combined with clinical and pathological data as well as an analysis of the two most frequent mutations in ccRCC: 
VHL and PBRM1.  
 
121 ccRCCs were collected from patients surgically treated in 19 French and one Belgian surgical departments 
from 1994 to 2011. All these patients developed synchronous or metachronic metastases and were treated in the 
metastatic setting with sunitinib as first-line anti-VEGF-targeted therapy. Global mPFS was 13 months and global 
mOS 27 months.  
 
Based on mRNA expression data, we identified 4 robust molecular subgroups of ccRCCs: ccrcc1, -2, -3 and -4, 
with a relative frequency of 33%, 41%, 11% and 15%, respectively. This molecular transcriptomic classification of 
m-ccRCC is in agreement with the previously published transcriptomic analyses of Brannon et al. [1][2], who 
identified three subgroups: ccA, ccB and Cluster_3, with a refinement of ccB in two sub-entities in our 
classification. Our subgroup ccrcc1 and 4 correspond to Brannon’s ccB, our ccrcc3-subgroup to Cluster_3 and 
our-ccrcc2 subgroup to Brannon ccA. In order to identify these molecular subgroups we developed a 35-gene 
signature that could be useful to screen ccRCCs in the next future. 
 
mPFS and mOS were significantly different among the four subtypes (p=0.001 and 0.0003, respectively). The 
ccrcc3-tumours displayed the best mPFS (24 months) followed by ccrcc2-tumours (19 months), ccrcc1-tumours 
(13 months) and ccrcc4-tumours (8 months). For mOS, the corresponding data are: 50 months for ccrcc3-
tumours, 35 months for ccrcc2-tumours, 24 months for ccrcc1-tumours and 14 months for ccrcc4-tumours. The 
classification was the most significant covariate in univariate cox analysis and remained the only significant 
covariate in the multivariate cox model.  
Response to sunitinib defined by RECIST was clearly associated to the ccrcc-classification: ccrcc3-patients had a 
RR of 70%. In ccrcc2-, ccrcc1- and ccrcc4-patients this was respectively 53%, 41% and 20%. 27% of the ccrcc4-
patients and 23% of the ccrcc1-patients were progressive at the first CT-scan evaluation, compared to 3% for 
ccrcc2-patients. All ccrcc3-patients had clinical benefit. All the complete and long lasting PR (>44 months of PFS) 
patients were found in the ccrcc2- and ccrcc3-subgroups. 
Although we do not have a placebo-treated control group, the important and significant difference in RECIST 
response rate among subgroups admits us to state that these molecular subtypes have a predictive value for 
response to sunitinib.  
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Figure 2: (A) Association of sunitinib response with the unsupervised subgroups ccrcc1-ccrcc4 (left) and 
the Brannon subgroups (right). The p-values result from Fisher-exact tests. (B) Association of the four 
unsupervised subgroups with progression-free survival (PFS)  (left) and overall survival (OS) (right). Log-
rank p-values are on the top right. (C) Forest plots of the multivariate cox models for PFS and OS. For 
each pair of correlated covariates, a bivariate cox model was first built to select the more significant 
covariate to integrate in the multivariate cox model. 
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The molecular characterization of these subgroups leaded to the identification of specific characteristics in each 
subgroup, some of them associated directly with outcome.  
 
 
Figure 3: Barplot of the pathologic-molecular covariates associated with the four unsupervised 
subgroups (ccrcc1 to ccrcc4). Stars correspond to significant anova or fisher p-values: *** p-value<0.001, 
** p-value<0.01 and * p-value<0.05.  
 
The two subtypes enriched in non-responders to sunitinib, ccrcc1 and ccrcc4, shared common molecular 
characteristics such as up-regulation of MYC-targets or a hyper-methylated status strongly correlated with a 
polycomb stem cell phenotype. The ccrcc4-subtype showed specific pathological features such as more 
inflammation and sarcomatoid phenotypes. These findings are in accordance with our findings described in 
chapter 6 and 7, respectively. It also showed an up-regulation of cellular immune pathways and an omnipresent 
8q21.13 amplification. Tumours classified in ccrcc4 and ccrcc1 were less frequently mutated at PBRM1 and VHL 
genes. ccrcc2-tumours were most often VHL-mutated. 
Among the groups of tumours enriched in responders to sunitinib, the expression profile of ccrcc3-samples was 
similar to that of normal kidney samples concerning metabolic pathways and transporter activities, similarly to the 
Cluster_3 described by Brannon [2]. The ccrcc3-subgroup also showed a methylation profile similar to that of 
normal kidney samples. Hypoxia pathways were not activated in ccrcc3-tumours. The ccrcc2-subgroup was not 
characterized by specific pathways; it always showed an intermediate expression signature, comprised between 
ccrcc3 and (ccrcc1+ccrcc4) related profiles. In ccrcc2-tumours cellular response to hypoxia was not as important 
as in the ccrcc1- and ccrcc4-subtypes. 
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Figure 4: Representation of the mean expression level of differentially regulated pathways between the 
four subgroups. Pathways are sorted by the difference between the ccrcc4-subgroup and the normal 
sample (NL). For a given pathway, samples are sorted by mean expression value.  
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CONCLUDING DISCUSSION AND PERSPECTIVES 
 
Several years after approval of anti-VEGF-targeted therapy for locally advanced and metastatic ccRCC, 
investigation is running in order to predict responses on these therapies and in order to determine the reasons of 
primary or secondary resistance. The aim of this study was to discover new clinical, biochemical, pathological, 
molecular and genetic markers predictive for response and/or prognostic in m-ccRCC patients treated with anti-
VEGFR-TKIs.  
 
1. The contribution of our work to this research field 
 
This research project contributes to a better understanding of the mechanisms of sensitivity or resistance to anti-
VEGFR-TKIs in m-ccRCC and to a more precise estimation of the RR, PFS and OS in m-ccRCC patients treated 
with anti-VEGFR-TKIs. 
 
1. We were among the first to describe the negative impact of the presence of bone metastasis in m-ccRCC 
on outcome. The presence of bone metastasis does not seem to have an important predictive value, but rather a 
prognostic value. We also observed that patients with metastatic spread limited to the lungs and lymph nodes had 
the best outcome and that the combination of bone and liver metastases correlated with poor outcome. Since the 
publication of our results in 2010, several other publications reported on the negative impact of bone metastases 
on outcome. In a pooled analysis of 1.067 predominantly clear cell mRCCs treated with sunitinib in six trials, the 
presence of bone metastases was significantly associated with lower RR and poorer OS (148). In a retrospective 
analysis of 2.027 mRCC patients treated with targeted therapies, the presence of bone and/or liver metastases 
correlated with poorer outcome. Patients combining bone and liver metastases had a particularly poor outcome 
(149). Possible mechanisms that could explain why the presence of bone metastases are an adverse factor for 
outcome are: (A) the vicious circle of mutual stimulation between osteoclasts and tumour cells in the bone. (B) 
RCCs with bone metastases could be a more aggressive subtype of RCCs. (C) Anti-VEGFR-TKIs could be less 
efficient in the bone micro-environment than at other metastatic sites and (D) in case of bone metastasis, the 
treatment with anti-VEGFR-TKIs could be more often interrupted due to skeletal related events. In accordance 
with mechanism (A), we could describe the positive impact of concomitant therapy associating anti-VEGFR-TKIs 
with bisphosphonates, which are bone resorption inhibitors in presence of bone metastases.  
 
2. We added evidence that polymorphisms in genes involved in sunitinib pharmacokinetics and more 
precisely in the ABCB1 efflux pump, have an impact on outcome in m-ccRCCs treated with sunitinib. 
Polymorphisms in the efflux pump are thought to influence sunitinib plasma levels. Although we did not have 
access to dosing of sunitinib plasma levels, we have indirect evidence for such a relationship. Patients with the 
variant associated with a more active efflux pump, had not only a poorer outcome on sunitinib, but also a longer 
time-to-dose-reduction, indicating that in these patients the sunitinib plasma levels might be lower than in patients 
with the wild-type ABCB1. If these findings would be validated in future trials, they could lead to the identification 
of a subgroup of patients in which a dose escalation to 62.5 mg/day and even 75 mg/day of sunitinib could safely 
be performed. We also validated previously published associations between polymorphisms in the cytochrome 
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CYP450 3A4 regulators NR1/2 and NR1/3 and outcome on sunitinib. As these polymorphisms are associated with 
TKI-kinetics and not with the malignancy of the tumour, they are not prognostic, but they have a predictive impact.  
 
3. We validated the impact of polymorphisms in VEGFR3 on outcome in m-ccRCCs treated with sunitinib 
and we were the first team to show the association between polymorphisms in VEGFR1 and outcome. Patients 
with the SNP rs307826 variant in VEGFR3 have a poorer outcome when treated with sunitinib. This finding is of 
interest because in the meantime, it was shown by Garcia-Donas et al. that patients with the variant VEGFR3 
rs307826 polymorphism had a lower expression of VEGFR3 (145). Moreover, VEGFR3 is highly expressed in tip 
cells, which are necessary for the sprouting of new vessels (150). Our findings concerning the polymorphism 
rs9582036 in VEGFR1 are also interesting, because in pancreatic adenocarcinomas treated with chemotherapy 
with or without bevacizumab, this variant was shown to be a predictive factor.  
 
4. We published the largest series in literature analysing the impact of baseline serum C-reactive protein 
(CRP) levels on outcome in m-ccRCC patients treated with sunitinib. Baseline CRP-levels were associated with 
PFS and OS on multivariate analysis. We were able to improve the accuracy of the IMDC prognostic score by the 
addition of baseline CRP-levels. As most of the clinical and biological parameters associated with outcome, we 
think that this biomarker has a prognostic value and that high CRP-levels are associated with a more aggressive 
disease. Accordingly, on the contrary, we found a RR as high as 72% in patients with a good IMDC prognostic 
score and normal baseline CRP-levels. Thus, this parameter might also have an additional predictive value.   
 
5. We added evidence that sarcomatoid dedifferentiation in 25% or more of the tumoral volume of the 
primary tumour has a negative impact on outcome in m-ccRCC patients treated with anti-VEGFR-TKIs.  
Moreover, our team recently published that in a series of 20 ccRCC patients treated with sunitinib, microRNA-141 
was significantly down-regulated in tumours poorly responding to sunitinib. This seemed spatially linked to EMT in 
vivo. Reintroduction of microRNA-141 in vitro reversed EMT and decreased cell viability in hypoxic conditions 
(151). 
 
6. Finally, through our multi-omics analysis of 121 ccRCC tumours, we were capable for the first time to 
show the predictive value of a mRNA expression profile based classification of ccRCCs on outcome when treated 
with sunitinib in the metastatic setting. Our classification is similar to formerly published classifications showing an 
impact on prognosis after nephrectomy. Nevertheless, we described significant differences in RR among the 
subgroups, showing that on top of a prognostic value, this classification has also a predictive value. In our 
analysis, tumours without activation of pathways involved in cellular response to hypoxia or with a limited 
activation of these pathways responded better than tumours with an important activation of these pathways. On 
the opposite,  upregulation of genes associated with immune response as well as the importance of immune 
infiltrates in the tumour were associated with poorer outcome, a finding that can easily be correlated with the 
association between baseline CRP-levels and outcome. The subgroup with the poorest outcome had an important 
incidence of sarcomatoid dedifferentiation, chromosome 8q amplifications and c-myc target transcription and a 
stem cell phenotype.  
 
Unfortunately, up to now, not any single parameter allows us to predict efficacy or resistance to anti-VEGFR-TKIs 
nor to preclude some patients from therapy with anti-VEGFR-TKIs. Efficacy or resistance seem rather to be the 
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result of multiple parameters. In the absence of a single predictive biomarker, these parameters could be 
combined in scoring systems predicting the probability of sensitivity (response) or resistance. 
 
2. New hypothesis on the working mechanisms of anti-VEGFR-TKIs and of resistance 
 
Taking together different experimental observations, we can emit the following hypotheses on the mechanism of 
action of anti-VEGFR-TKIs and on mechanisms of resistance.  
 
2.1. Inhibition of the activated VEGF-pro-angiogenic pathway in hyper-vascular tumours 
 
The efficacy of anti-VEGF-targeted therapy in m-ccRCC is in part explained by the inhibition of the activated 
VEGF-pro-angiogenic pathway in these hyper-vascular tumours. The arguments are the following:  
 ccRCCs are the tumours that most express VEGF, through omnipresent VHL-dysfunction. Therefore, 
neo-angiogenesis is particularly important in ccRCC, which are hyper-vascular tumours. Moreover, anti-
VEGF-targeted therapy is clinically less useful in non-ccRCCs, which are tumours without VHL-
impairment (72, 74).  
 Anti-VEGFR-TKIS with high affinity for VEGFR1, -2 and -3 such as axitinib as well as purely anti-VEGF-
directed antibodies such as bevacizumab have proven efficacy in m-ccRCC.  
 After the start of anti-VEGFR-TKIs, normalization of anarchic neo-vessels occur.  
 Several reports suggest an association between the levels of expression of proteins of the VEGF-
pathway and outcome.  
 
2.2. Induction of normoxia, rather than increase of hypoxia 
 
There are arguments to believe that efficacy of anti-VEGF-targeted therapy is probably associated with induction 
of normoxia, rather than with increase of hypoxia, through a regression, but most of all normalization of the 
tumoral vasculature, with lowering of the interstitial pressure and better oxygen delivery. The arguments are the 
following: 
 
 Tumour hypoxia is known to be a factor of poor prognosis because it renders a tumour more aggressive, 
leading to higher levels of HIF and thus higher expression of genes involved in cell cycle, invasion, and 
progression in tumour vasculature, tumour proliferation, and metastatic spread. Thus, hypoxia should be 
avoided and normoxia should be the target of therapy. Through the reduction and normalization of blood 
vessels, anti-VEGF-targeted therapy seems to lead to better oxygen delivery in the tumour, because the 
newly formed vasculature is poorly functional, with tortuous immature vessels, anarchic interconnections, 
increased capillary permeability, and fluid leakage into the interstitial space resulting in increased 
interstitial pressure, impairing oxygen diffusion and thus inducing tumour hypoxia.  As a consequence, 
restoring normoxia or at least lowering hypoxia seems to be an important part of the mechanism of 
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action of anti-VEGF-targeted therapy. Moreover, tumours that remain hypoxic under VEGF-blockade, will 
activate VEGF-independent neo-angiogenesis. In normoxic tumours there will be no need for the 
activation of alternative pro-angiogenic pathways.   
 
 Recent work by Hugonnet et al. seems to confirm this hypothesis. In a series of 41 mRCC patients, 
tumour hypoxia was assessed before the start of sunitinib and after one month of sunitinib by an 
18
F-
fluoromisonidazole positron emission tomography (PET)-CT-scan. 
18
F-fluoromisonidazole accumulates 
intracellularly in hypoxic cells. At baseline, tumour hypoxia as assessed by 
18
F-fluoromisonidazole 
PET/CT uptake in mRCC was less frequent and less pronounced than initially suspected. Patients with 
initially hypoxic targets had shorter PFS than patients with non-hypoxic targets. OS was comparable 
between hypoxic and non-hypoxic patients, but the median follow-up was probably too short to notice 
differences. Under therapy with sunitinib,
 18
F-fluoromisonidazole uptake significantly decreased in initially 
hypoxic target metastases but did not increase in targets which were initially normoxic: the latter 
metastases did not become hypoxic (152). 
 
 
Figure 1.: 75% of patients with hypoxic metastases were free of progressive disease at 4.8 months 
(95%CI, 2.99–11.83), compared with 11.3 months (95%CI, 3.08–36.9) for other patients (p = 0.02). 
Courtesy of Hugonnet et al. (152) 
 
 Among our four expression-profile based subgroups ccrcc1 to ccrcc4, there was an important difference 
in expression of pathways associated with cellular response to hypoxia. The good prognostic ccrcc2- 
and ccrcc3-subgroups had a lower expression of these pathways, meanwhile the poor prognostic 
ccrcc1- and ccrcc4-subgroups displayed an important expression of these pathways.  
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2.3. The balance normoxia versus hypoxia: the trigger of response to anti-VEGF-targeted therapy? 
 
Therefore, our hypothesis is that the balance normoxia versus hypoxia or neo-angiogenesis versus hypoxia could 
be the ultimate trigger of response to anti-VEGF-targeted therapy.  
 A tumour with important neo-angiogenesis, but with reduced hypoxia, will respond to anti-VEGFR-
targeted therapy, because normoxia can be restored. On the opposite, a tumour that has an important 
hypoxia, in presence or absence of an important neo-angiogenesis, will stay hypoxic, even if anti-VEGF-
targeted therapy could normalize the neo-vasculature.  
 Hypoxia will be more important and more difficult to reverse in aggressively growing tumours and in 
important tumoral masses. This is consistent with the findings that tumour burden is associated with poor 
outcome in m-RCC patients treated with anti-VEGF-targeted therapy (128, 129): the larger the tumoral 
lesions, the higher the intratumoral hypoxia.  
 Tumours with EMT, which is induced by c-myc and can be associated with a sarcomatoid phenotype on 
microscopy, switch to a hypoxia-resistant growth modus, with a reduced need for neo-angiogenesis. In 
these tumours, reduction and normalization of the vessels will not affect tumour growth.  
 In ccRCCs, due to frequent VHL-impairment, there is an important neo-angiogenesis compared to the 
relatively low importance of the hypoxia. Therefore, in opposition to other tumour types, anti-VEGF-
targeted therapy can work in ccRCCs in monotherapy. 
Assuming that the reduction of neo-vessels leads to tumoral reduction with restoration of normoxia, the question 
remains whether the communication between endothelial cells and tumoral cells is merely oxygen pressure, or if 
there is any other tumour stimulating growth factor that would be secreted by endothelial cells. 
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Figure 2: This scheme explains the hypothesis that sensitivity/resistance to anti-VEGF-targeted therapy in 
m-ccRCC might be the result of the balance neo-angiogenesis/hypoxia.  
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3. Future research perspectives 
 
3.1. Expression-profile based ccRCC classification 
 
The analyse of additional primary nephrectomy specimens in order to validate the impact of the expression-based 
ccRCC-classification as a prognostic and predictive marker is foreseen. This additional tumour series will allow us 
to enrich each subgroup of tumours with additional samples in order to increase the power to detect specific 
mutations, molecular characteristics and pathogenic events in each subgroup. Good candidate genes for 
additional mutation analysis, given the significant differences in epigenetic characteristics in each subgroup, are 
genes associated with chromatin modification such as BAP1, SETD2 and UTX. Until today, no association 
between the mutation, hyper-methylation or LOH of VHL and outcome on anti-VEGF-targeted therapy has been 
shown, although the lack of functional VHL-protein could stabilise HIF and thus lead to VEGF-mediated neo-
angiogenesis (140, 141). Therefore, we will study alternative VHL-impairment mechanisms such as transcription 
elongation factor B (TCEB1)-mutations (40) and alternative VHL-independent HIF-stabilisers such as the oxygen 
sensors prolylhydroxylase (PHD, also called egl-9 family hypoxia-inducible factor-1 or EGLN1) and factor 
inhibiting HIF (FIH) (153). We will take a closer look at EMT and at the interaction between endothelial cells and 
tumour cells with special attention for angiocrine factors that might influence tumour growth. Finally, we will study 
the impact of HIF1-alpha and HIF2-alpha on cell cycle induction and outcome.  
As the efficacy on anti-VEGF-targeted therapy is in most cases based on the response of the metastases on CT-
scans and as these metastases often appear several years after resection of the initial tumor, molecular analysis 
of metastatic sites is warranted. More precisely, we will analyse the stability of the expression-based ccRCC 
classification through the molecular characterisation of metastasectomy specimens.  
Additionally, we intent to study if the expression-based ccRCC classification could help in the decision to perform 
a metastasectomy. In fact, after initial nephrectomy, or at the moment of initial diagnosis of the kidney tumour, 
patients can present with a single metastasis. The clinicians have then to decide if they perform a 
metastasectomy or not. This intervention being only useful if the patient will not rapidly recur with new and 
multiple metastasis. At the present moment, only clinical and biochemical criteria are available to help in the 
decision.  
 
3.2. Germ-line polymorphisms 
 
Given its possible predictive value, we intent to validate the impact of SNP rs9582036 in VEGFR1 on outcome in 
m-ccRCCs treated with anti-VEGFR-TKIs. The study of polymorphisms in the VHL-gene, known to have a 
functional impact, will help us to understand better the impact of VHL on outcome in m-ccRCC patients treated 
with anti-angiogenic drugs. We plan to validate the other associations between polymorphims and outcome 
(SNPs in VEGFR3, NR1/2, NR1/3, ABCB1) in a prospective way and to combine them in a scoring system. The 
impact of polymorphisms in genes involved in sunitinib pharmacokinetics on sunitinib plasma levels will be 
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studied. Finally, we intent to study the association between the presence of VEGFR1 and VEGFR3 
polymorphisms and the level of expression of these proteins in tumoral samples as well as micro-vessel density.  
 
 
3.3. Response prediction in second-line therapy 
 
As a consequence of the availability of several anti-VEGFR-TKIs and mTOR-inhibitors, several sequential 
combinations are possible. Two phase III studies showed a benefit of everolimus (compared to placebo) and 
axitinib (compared to sorafenib) in the second-line metastatic setting (6, 20). Nevertheless, response on second-
line therapy is generally poor with a mPFS of 3-4 months for everolimus and sorafenib and 6 months for axitinib. 
Long lasting responses and important tumour shrinkage, as seen in the first-line setting, are seldom seen in 
second-line therapy. Moreover, an important part of the patients are progressive after only two months of therapy, 
which is comparable to the poor results observed in placebo-treated patients. The comparison of a switch to 
mTOR-inhibitors or the continuation of VEGFR-blockade in the second-line setting after progression on a first-line 
VEGFR-inhibition, is ongoing, but provisional data does not seem to show important differences. Therefore, we 
would like to study factors associated with outcome in the second-line setting in order to identify who could be the 
patients with a potential benefit of a second-line therapy. This study can have important clinical implications: it can 
identify patients who only will have side effects and no benefit. Moreover, given the high costs of targeted 
therapies, the identification of a group of patients resistant to second-line targeted therapies can also have a 
beneficial financial impact for the health insurance system. 
 
3.4. Bone metastases and outcome 
 
We will pursue our research on the impact of the presence of bone metastases in m-ccRCC. 
Since January 2012, patients starting on anti-VEGFR-TKI therapy at the University Hospitals Leuven, undergo a 
baseline whole-body MRI (WBMRI) in order to study if this new imaging technique can improve the detection of 
bone metastasis, compared to standard investigations such as CT-scan and bone scintigraphy. In patients with 
bone metastases, by serial WBMRIs during therapy with anti-VEGFR-TKIs, we also want to document if targeted 
therapy is as helpful in bone metastasis as it is in other metastatic sites.  
Finally, we want to validate in a prospective observational trial our data on benefits and risks of concomitant TKI 
and bisphosphonate use in m-ccRCCs with bone metastases. A randomized study of anti-VEGFR-TKIs with 
bisphosphonates versus anti-VEGFR-TKIs with placebo, although meaningful, is difficult to implement for ethical 
reasons because bisphosphonates are important in preventing skeletal related events, which are particularly 
frequent in mRCCs with bone metastases. Not only patients treated with bisphosphonates will be considered, but 
also patients treated with other bone sparing drugs like denosumab.  
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ABSTRACT OF THE RESEARCH 
 
Based upon the knowledge that neo-angiogenesis plays a critical role in the progression of locally advanced and 
metastatic ccRCC, efficient drugs targeting the VEGF-pro-angiogenic pathway were developed during the last 
decade.  
These drugs, mainly anti-VEGFR-TKIs, which are now increasingly used in clinical practice, allow to elicit 
responses and to prolong survival in mRCC. Unfortunately they can induce severe side-effects and are very 
expensive. Our project was to identify/discover clinical factors, pathological and biochemical characteristics, and 
new molecular markers allowing to predict response and outcome in m-ccRCC patients treated with anti-VEGFR-
TKIs. Additionally, independently of the systemic treatment used, we also investigated whether some of these 
factors were of prognostic value in m-ccRCC patients. 
We identified as clinically relevant for prognosis in m-ccRCC patients the following pathological and biochemical 
features: (A) The presence of bone metastases, with or without other metastatic localizations, generally indicate a 
poor prognosis. (B) Elevated baseline CRP-levels and (C) the presence of an important component of 
sarcomatoid dedifferentiation in the primary tumour and/or the metastasis are also associated with a more 
aggressive behaviour and worse outcome.  
We also found several biochemical markers with a (potential) predictive value, among them variants in the 
ABCB1-efflux pump and in the VEGFR1 and -3. 
These newly identified clinico-pathological and biological characteristics of m-ccRCC patients and of their tumors, 
as well as other markers described in the literature, allow us to predict more precisely the outcome in an individual 
patient treated with anti-VEGFR-TKIs. m-ccRCC may respond to targeted anti-angiogenic therapy, but m-ccRCC 
with an important sarcomatoid component are nearly always refractory. We showed that m-ccRCC patients with 
bone metastases benefit from agents blocking the osteoclastic activity like bisphosphonates. When the latter or 
newer agents like denosumab are combined to anti-VEGFR-TKIs, better results can probably be achieved, but 
caution and preventive measures are warranted in view of an increased risk of osteonecrosis of the jaw. 
Moreover, based on a multi-omics analysis using unsupervised clustering of expression data, we identified four 
molecular subgroups of ccRCCs, each of them displaying distinct and typical histologic, mutational, epigenetic, 
and cytogenetic characteristics. When treated with the anti-VEGFR-TKI sunitinib, these four subgroups behaved 
differently in terms of RR, PFS and OS: two subgroups displayed a good outcome with high RRs, while the two 
remainders had low RRs and very short survival. As a consequence, this new molecular ccRCC classification 
distinguishing these subgroups has certainly a prognostic value; further prospective validation of its predictive 
interest is warranted and ongoing, in order to see whether anti-VEGF-targeted therapy could be selectively 
indicated or omitted in some of them.  
Finally, our findings are hypothesis-generating, contributing to a better understanding of the mechanisms of 
sensitivity or resistance of m-ccRCC to anti-VEGFR-TKIs. These drugs block further development of neo-
angiogenesis, and may even restore normal vasculature in m-ccRCC, leading to better oxygenation of tumoral 
deposits, thereby interrupting the vicious circle of hypoxia-induced tumor progression. This is the case in many m-
ccRCC, while sarcomatoid tumors, which generally display little or no neo-angiogenesis, are tumors progressing 
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under irreversible hypoxic conditions. We thus emit the hypothesis that response in m-ccRCCs treated with anti-
VEGFR-TKIs is highly dependent of the balance between neo-angiogenesis and hypoxia. 
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SAMENVATTING 
 
Tot enkele jaren geleden was het gemetastaseerd heldercellig niercelcarcinoom een erg moeilijk te behandelen 
ziekte. Sinds 2005 beschikken we echter over een aantal nieuwe geneesmiddelen om deze ziekte te bestrijden. 
Deze geneesmiddelen trachten de aanmaak van bloedvaten in tumoren tegen te gaan en worden  
bloedvatremmers genoemd. Opdat een tumor of de uitzaaiingen van een tumor zouden kunnen groeien, zijn er 
immers nieuwe bloedvaten nodig die zuurstof en energie aan de kankercel kunnen bezorgen. In de jaren zeventig 
reeds ontstond het idee om tumorgroei te vertragen door nieuwe en bestaande bloedvaten te blokkeren.  
Het heldercellig niercelcarcinoom is precies een ziekte waar er een belangrijke aangroei is van nieuwe 
bloedvaten. Mogelijks is het daarom dat bloedvatremmers de meest efficiënte therapie ooit zijn in de behandeling 
van deze ziekte. Sunitinib, pazopanib, axitinib, sorafenib en bevacizumab worden nu routinematig met succes 
gebruikt bij de behandeling van het gemetastaseerd heldercellig niercelcarcinoom. Ongeveer 40% van de 
patiënten die met bloedvatremmers behandeld worden, ondervindt een regressie van de tumoren. Bij een andere 
40% kan de ziekte worden gestabiliseerd. Bij 20% van de patiënten blijken deze nieuwe therapieën echter niet 
werkzaam. Bovendien zullen de meeste patiënten, bij wie in eerste tijd een stabilisatie of regressie van de tumor 
wordt vastgesteld, uiteindelijk terug hervallen: hun tumor en uitzaaiingen beginnen opnieuw te groeien binnen een 
periode van gemiddeld ongeveer één jaar.  
Alhoewel deze geneesmiddelen reeds een tiental jaren gebruikt worden, is hun werkingsmechanisme nog niet 
volledig ontrafeld en is er bijzonder weinig gekend over de mechanismen van resistentie. Dit onderzoeksproject 
had als doel deze vragen te beantwoorden. De resultaten van dit onderzoek moeten ons in de toekomst helpen 
om het juiste geneesmiddel te geven aan de juiste patiënt zodat we een maximale efficiëntie kunnen bereiken bij 
patiënten bij wie deze geneesmiddelen werkzaam zijn. Aan patiënten bij wie deze geneesmiddelen niet efficiënt 
zijn, zullen andere, nog te ontwikkelen geneesmiddelen moeten worden voorgeschreven. Zij zullen de 
bloedvatremmers niet meer voor niets innemen en bespaard blijven van bijwerkingen. Dit onderzoek zal op 
termijn dan ook bijdragen tot het beter benutten van de beschikbare financiële middelen in de gezondheidszorg.  
 
In ons onderzoek hebben wij verschillende factoren gevonden die de werkzaamheid van deze geneesmiddelen 
gedeeltelijk kunnen verklaren. 
 We konden aantonen dat de aanwezigheid van botmetastasen een ongunstige prognostische factor is. 
Aansluitend toonden we aan dat het toevoegen van botversterkers de efficiëntie van de therapie kan 
verbeteren.  
 We toonden aan dat varianten in genen betrokken bij de absorptie in de darm en de metabolisatie van 
sunitinib een invloed kunnen hebben op de efficiëntie van de therapie. Deze varianten geven aanleiding 
tot een betere absorptie of tot minder afbraak van het geneesmiddel.  
 We beschreven de impact van varianten in eiwitten betrokken bij de aanmaak van nieuwe bloedvaten, 
meer bepaald in de VEGF-receptoren- 1 en -3, op de resultaten bij behandeling met sunitinib. 
 We hebben aangetoond dat slechtere resultaten bekomen worden onder behandeling met sunitinib bij 
patiënten met een inflammatoire toestand (een hoog C-reactief proteïne) bij aanvang van de therapie. 
 De aanwezigheid van een component van sarcomatoïde dedifferentiatie in de primaire tumor van 25% of 
meer van het totale tumor-volume is ook een negatieve prognostische factor onder behandeling met 
bloedvatremmers.  
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 Tenslotte waren we in staat om het heldercellig niercelcarcinoma in te delen in vier subgroepen op basis 
van moleculaire kenmerken, en aan te tonen dat twee subgroepen geassocieerd zijn met een met goed 
resultaat en twee subgroepen met een slecht resultaat onder behandeling met  sunitinib.  
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